On this page
Quick Reference
Overview and Recommendations
Background
- •Amyloidosis is a heterogeneous group of diseases defined by extracellular deposition of insoluble fibrils from misfolded precursor proteins. The most common systemic type is AL (immunoglobulin light chain) amyloidosis, with an incidence of 8-12 per million, followed by ATTR (transthyretin) and AA (serum amyloid A).
- •AL amyloidosis originates from a small clonal plasma cell population, often harboring t(11;14) (50% of cases), that secretes amyloidogenic monoclonal light chains. The bone marrow plasma cell burden is typically low but can overlap with multiple myeloma.
- •Cardiac involvement dominates prognosis: 60-75% of AL patients have cardiac amyloidosis, presenting as HFpEF with restrictive physiology. Untreated median survival is 12-18 months; modern therapy achieves 5-year survival >70% with deep hematologic response.
- •Other major types: ATTRwt (wild-type, older men, carpal tunnel syndrome, cardiomyopathy), ATTRv (hereditary, neuropathy/cardiomyopathy), and AA (secondary to chronic inflammation, primarily renal). Accurate typing dictates treatment, making mass spectrometry the gold standard.
- •Pathophysiology involves misfolding of normally soluble proteins into beta-pleated sheet fibrils; oligomeric intermediates are the primary cytotoxic species, causing oxidative stress and organ dysfunction even before fibril deposition.
Evaluation
- •Suspect AL amyloidosis in patients >50 years with unexplained nephrotic syndrome, restrictive cardiomyopathy, peripheral neuropathy, hepatomegaly, macroglossia, or periorbital purpura. Also consider ATTRwt in older men with carpal tunnel syndrome preceding heart failure.
- •Ask about exertional dyspnea, orthopnea, edema, weight loss, early satiety, orthostatic dizziness, paresthesias, and family history of neuropathy or cardiomyopathy.
- •Examine for orthostatic hypotension, jugular venous distension, peripheral edema, hepatomegaly, macroglossia, periorbital purpura, and length-dependent sensory loss with diminished ankle reflexes.
- •Order serum immunofixation, urine immunofixation, and serum free light chain (FLC) assay as initial screen. The combination detects 92% of AL cases. Also obtain NT-proBNP and cardiac troponin for staging.
- •Perform transthoracic echocardiography with global longitudinal strain and cardiac MRI with T1 mapping to assess cardiac involvement. Fat pad aspirate and bone marrow biopsy with Congo red staining diagnose amyloid; mass spectrometry (LC-MS/MS) is the gold standard for typing.
- •Apply Mayo 2012 staging: NT-proBNP ≥1800 pg/mL, troponin T ≥0.025 ng/mL, dFLC ≥18 mg/dL. Stage IIIb (NT-proBNP >8500 ng/L) identifies ultra-high risk with median OS 9 months despite therapy.
- •Consider genetic testing for TTR mutations in patients with atypical features, no clonal dominance, or family history. Cardiac biopsy may be needed if non-invasive tests are inconclusive.
- •Assess renal function (eGFR, proteinuria) and coagulation profile (fibrinogen, D-dimer) due to bleeding risk from hyperfibrinolysis and factor X deficiency.
Management
- •Initiate daratumumab-CyBorD for newly diagnosed AL. Daratumumab 1800 mg SC weekly cycles 1-2, then q2w cycles 3-6, then q4w up to 2 years. CyBorD: bortezomib 1.3 mg/m² SC, cyclophosphamide 300 mg/m² PO/IV, dexamethasone 40 mg PO/IV on days 1,8,15,22 of a 28-day cycle for 6 cycles.
- •Titrate doses: reduce bortezomib for neuropathy, cyclophosphamide for renal impairment (CrCl 10-50: 75% dose), dexamethasone to 20 mg weekly in frail patients to avoid volume overload and infections.
- •Monitor hematologic response after each cycle: CR requires normal FLC ratio and negative immunofixation; VGPR is dFLC <40 mg/L; PR is >50% dFLC reduction. Aim for VGPR or better within 3 months.
- •Assess cardiac response: NT-proBNP decrease >30% and >300 ng/L defines cardiac response. Graded criteria (cardiac CR, VGPR, PR, NR) predict 5-year survival (93%, 79%, 65%, 33% respectively).
- •For ATTR cardiomyopathy, vutrisiran 25 mg SC q12w or patisiran 0.3 mg/kg IV q3w. In octogenarians, tafamidis reduces all-cause mortality (HR 0.51). For ATTR polyneuropathy, inotersen 300 mg SC weekly.
- •For AA, aggressively control underlying inflammation to achieve SAA <10 mg/L; target <4 mg/L for optimal survival.
- •What NOT to do: avoid ASCT as first-line in unselected patients; avoid dexamethasone 40 mg beyond 6 cycles; avoid bortezomib in NYHA III/IV HF without caution; avoid digoxin in cardiac amyloidosis.
- •When to refer: to hematology for AL; to cardiology for advanced cardiac imaging; to nephrology for renal biopsy or dialysis; to neurology for neuropathy.
- •For acute bleeding, tranexamic acid 1 g IV q8h (adjust for eGFR <30). For AF with cardiac amyloidosis, use DOACs over warfarin; LAAC is alternative for high bleeding risk.
- •Escalation: if no PR after 2-3 cycles, switch to bortezomib-melphalan-dexamethasone, lenalidomide-based therapy, or BCMA-directed therapy. Anti-BCMA CAR-T achieves 94% ORR but with high early mortality in advanced cardiac disease.
- •Discharge criteria: hemodynamic stability, controlled heart failure, no active bleeding, plan for ongoing chemotherapy. Re-stage at 3 and 6 months; stage migration predicts worse survival.
Board Review — High Yield
- •Congo red stain - apple-green birefringence under polarized light is diagnostic for amyloid.
- •t(11;14) - most common cytogenetic abnormality in AL, present in ~50%, associated with adverse prognosis and targetable with venetoclax.
- •Mayo 2012 staging - uses NT-proBNP, troponin T, and dFLC to stratify prognosis; stage IV median OS 5.8 months.
- •Dara-CyBorD - standard first-line therapy for AL; ANDROMEDA trial showed CR 53% vs 18% and reduced organ deterioration (HR 0.58).
- •Mass spectrometry - gold standard for amyloid typing, sensitivity 98-100%; immunofixation is complementary.
- •ATTRwt - often misdiagnosed as HFpEF; consider in older men with carpal tunnel syndrome and thick LV walls.
- •SAA target - in AA, maintain SAA <4 mg/L for optimal survival; risk of death 18-fold higher if SAA >155 mg/L.
- •Hyperfibrinolysis - dominant bleeding mechanism in AL; treat with tranexamic acid 1 g IV q8h.
- •DOACs preferred - for atrial fibrillation in cardiac amyloidosis over warfarin; meta-analysis shows reduced thromboembolism without increased major bleeding.
- •Cardiac response - NT-proBNP decrease >30% and >300 ng/L defines cardiac response; 5-year OS 93% for cardiac CR vs 33% for no response.
Deep Dive — Evidence Details
1. Definition, Classification & Nomenclature
- ▸Amyloidosis is classified by the precursor protein (AL, AA, ATTR, Aβ2M, etc.), which dictates entirely different treatment strategies.
- ▸Accurate typing requires specialized techniques: immunohistochemistry combined with clinical and genetic data, or gold-standard mass spectrometry-based proteomics [1,2,3].
- ▸The concept of monoclonal gammopathy of clinical significance (MGCS) encompasses AL amyloidosis and other disorders driven by a small B-cell/plasma cell clone [7].
Amyloidosis is a heterogeneous group of diseases defined by the extracellular deposition of insoluble fibrillar proteins derived from misfolded precursor proteins. The clinical of amyloidosis is based on the treatment of the underlying etiology, and accurate identification of the protein causing the amyloidosis is of paramount importance [2]B3b.
Synonyms and Related Terms
- AL amyloidosis (primary amyloidosis): immunoglobulin light chain-derived.
- AA amyloidosis (secondary amyloidosis): serum amyloid A protein-derived.
- ATTR amyloidosis: transthyretin-derived; includes wild-type (ATTRwt, formerly senile systemic amyloidosis) and variant (ATTRv, formerly familial amyloid polyneuropathy/cardiomyopathy).
- Aβ2M amyloidosis: beta-2 microglobulin-derived, associated with long-term dialysis.
- Monoclonal gammopathy of clinical significance (MGCS): a term encompassing conditions driven by a small, indolent plasma cell or B-cell clone that causes organ damage via the monoclonal protein, including AL amyloidosis [7]D5.
- Monoclonal gammopathy of thrombotic/hemorrhagic significance (MGTHS): a proposed subtype of MGCS where the monoclonal protein produces hemostatic abnormalities [7]D5.
Classification by Precursor Protein
Amyloidosis is classified by the type of fibril precursor protein, which dictates treatment. The most common systemic forms are AL, AA, and ATTR. The table below summarizes the major types:
| Type | Precursor Protein | Key Features |
|---|---|---|
| AL (light chain) | Immunoglobulin light chain (κ or λ) | Most common systemic type; associated with ; can involve any organ except brain [1]C4. |
| AA (serum amyloid A) | Serum amyloid A protein | Secondary to chronic inflammation (e.g., autoimmune diseases, ); predominantly renal [6]B2b. |
| ATTRwt (wild-type transthyretin) | Transthyretin (wild-type) | Predominantly cardiac; older men; often underdiagnosed [9]B2a. |
| ATTRv (variant transthyretin) | Transthyretin (mutant) | Hereditary; neuropathy and/or cardiomyopathy; autosomal dominant. |
| Aβ2M | Beta-2 microglobulin | Dialysis-related; , arthropathy. |
| Others (e.g., ApoAI, ApoAII, fibrinogen, gelsolin) | Various | Rare hereditary forms; organ-specific deposition. |
Accurate typing is essential because treatment differs fundamentally: AL amyloidosis requires chemotherapy targeting the plasma cell clone, while AA amyloidosis is managed by controlling the underlying inflammatory condition, and ATTR amyloidosis is treated with stabilizers or gene silencers [1]C4[2]B3b[3]B3b. Immunohistochemistry on biopsy specimens, performed by a highly specialized pathologist, yields high accuracy when combined with clinical examination and genotyping [1]C4. However, laser microdissection and mass spectrometry-based proteomic analysis (LMD/MS) has emerged as the gold standard, achieving 98-100% specificity and sensitivity in clinical biopsy specimens [2]B3b[3]B3b.
Clinical Significance of Classification
Classification also informs prognosis and risk stratification. For example, the revised Mayo Clinic staging system for AL amyloidosis incorporates cardiac biomarkers (troponin T, NT-proBNP) and the difference between involved and uninvolved free light chains (FLC-diff) to stratify overall survival [4]B2b. The identification of a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype in AL amyloidosis, defined by flow-cytometric analysis of bone marrow plasma cells, independently predicts better outcomes [5]B2b. These concepts are discussed in detail in Section 6 (Staging, Risk Stratification & Prognostic Scoring).
The mechanisms by which misfolded proteins form amyloid fibrils and cause organ damage are discussed in the next section (Section 2: Pathophysiology & Mechanism).
Pearl: The single most important clinical decision in suspected amyloidosis is to determine the fibril type, AL, AA, or ATTR, because misclassification leads to inappropriate and potentially harmful therapy. Mass spectrometry-based proteomics on biopsy tissue is the diagnostic gold standard [2]B3b[3]B3b.
2. Pathophysiology & Mechanism
- ▸Amyloidosis pathogenesis is unified by misfolding of a precursor protein into cross-β fibrils, but the specific precursor (light chain, TTR, SAA) dictates organ tropism and treatment approach.
- ▸In AL amyloidosis, the small plasma cell clone harbors recurrent cytogenetic abnormalities (t(11;14) in ~50%) and produces light chains with N-glycosylation hotspots that drive aggregation and direct cellular toxicity.
- ▸ATTR amyloidosis results from tetrameric TTR destabilization by aging or mutation; RNAi and ASO therapies exploit this by reducing hepatic TTR production by ~80%.
Having classified amyloidosis by precursor protein, the common pathogenic thread is the misfolding of a normally soluble protein into insoluble beta-pleated sheet fibrils that deposit extracellularly, leading to progressive organ dysfunction. This process is driven by a combination of genetic predisposition, clonal expansion, and environmental triggers, with distinct mechanisms for each major type.
Amyloid Fibril Formation
All amyloid fibrils share a cross-β conformation, where stacked β-strands run perpendicular to the fibril axis. This structure is thermodynamically stable and resistant to proteolysis. Fibril formation proceeds through a nucleation-dependent polymerization: a critical concentration of misfolded monomers forms an oligomeric nucleus, which then rapidly elongates by adding monomers. The oligomeric intermediates are the primary cytotoxic species, disrupting cellular membranes, inducing oxidative stress, and activating pro-apoptotic pathways [52]D5.
AL Amyloidosis: The Plasma Cell Clone and Light Chain Toxicity
AL amyloidosis originates from a clonal plasma cell population, typically small (median bone marrow plasma cells <10%), that secretes a monoclonal immunoglobulin light chain (LC) with an amyloidogenic propensity [27]C4. The underlying clone harbors recurrent cytogenetic abnormalities: t(11;14) is the most frequent, occurring in ~50% of patients, and is associated with lower tumor burden but adverse prognosis [42]B2b[35]B2b. Other common aberrations include gain of 1q21, deletion of 13q14, and hyperdiploidy [43]B2b. In IgM-associated AL, the clone is often lymphoplasmacytic with MYD88 L265P mutations (58% of cases) and distinct biology [54]B2b.
Key molecular features of amyloidogenic LCs include:
- N-glycosylation hotspots: A specific N-glycosylation motif (NFT) in framework region 3 of κ LCs is enriched in AL compared with other monoclonal gammopathies, promoting aggregation [56]B3b.
- Intrinsic instability: Amyloidogenic LCs have lower thermodynamic stability, favoring misfolding and fibril assembly [44]D5.
- Direct cellular toxicity: Light chains induce mitochondrial oxidative stress, proteasome impairment, and autophagy in target cells (e.g., cardiomyocytes, podocytes) [38]D5. This toxicity correlates with organ dysfunction even before fibril deposition is visible.
The bone marrow microenvironment in AL shows generalized suppression of normal hematopoiesis, expansion of monocytes and distinct CD4+ T-cell subsets, and elevated tumor necrosis factor-α signaling [24]B3b. Clonal hematopoiesis of indeterminate potential (CHIP) is more frequent in AL than in age-matched controls (21%), particularly DNMT3A mutations, and is associated with t(11;14) [32]B2b.
ATTR Amyloidosis: Tetramer Destabilization
Transthyretin (TTR) is a homotetrameric protein secreted mainly by the liver. In ATTR amyloidosis, destabilization of the tetramer, either by age-related alterations (wild-type ATTR) or by pathogenic mutations (e.g., Val122Ile, Val30Met, G47R), promotes dissociation into monomers that misfold and aggregate [65]C4. Over 130 TTR mutations are known; they reduce tetramer thermodynamic and kinetic stability, accelerating amyloidogenesis [28]D5. RNA interference (patisiran) and antisense oligonucleotides (inotersen) reduce hepatic TTR production by ~80%, lowering circulating amyloid precursor [16]A1b[28]D5. ATTR cardiomyopathy is now recognized as a common cause of heart failure in older adults, especially with the Val122Ile mutation in individuals of African descent [59]B2a.
AA Amyloidosis: Acute Phase Response
AA amyloidosis results from sustained overproduction of serum amyloid A (SAA), an acute-phase reactant, in chronic inflammatory conditions (e.g., rheumatoid arthritis, familial Mediterranean fever). SAA is cleaved into AA fragments that deposit as fibrils, primarily in the kidneys and spleen. Inherited (e.g., MEFV mutations in FMF) confer risk through recurrent inflammation and elevated SAA [61]C4.
Organ Tropism and Cellular Toxicity
Organ damage in amyloidosis arises from both the physical disruption of tissue architecture by fibril deposits and the direct toxicity of misfolded proteins. Cardiac involvement in AL is driven by light-chain-induced oxidative stress, impaired calcium handling, and apoptosis of cardiomyocytes, leading to diastolic dysfunction and arrhythmias [51]D5. Renal amyloidosis damages glomerular basement membrane and podocytes, causing proteinuria. In ATTR, fibril deposition in the myocardium and peripheral nerves leads to progressive cardiomyopathy and polyneuropathy [28]D5.
Bleeding and Thrombotic Tendencies
Amyloid deposits in blood vessel walls increase capillary fragility, and light chains can interfere with coagulation factors (e.g., factor X deficiency) and platelet function [45]D5. Fibrinolytic activation may be enhanced by cross-β structure binding to tissue-type plasminogen activator [52]D5. These mechanisms explain the paradoxical risk of both bleeding and thrombosis in .
These pathogenic mechanisms set the stage for the and risk factors discussed next.
Pearl: ATTR amyloidosis results from tetrameric TTR destabilization by aging or mutation; RNAi and ASO therapies exploit this by reducing hepatic TTR production by ~80%.
3. Epidemiology, Etiology & Risk Factors
- ▸Incidence of AL amyloidosis is stable at 10-12 per million person-years, but prevalence has more than doubled from 2007-2015 due to improved survival.
- ▸N-glycosylation of monoclonal light chains is a potent risk factor for progression from MGUS to AL (21% vs 3% at 20 years), independent of the Mayo MGUS risk score.
- ▸Cardiovascular mortality in amyloidosis has not improved despite overall survival gains, highlighting a critical unmet need for targeted cardiac management.
The fibrillar deposition mechanisms outlined in the preceding section translate into distinct epidemiological patterns. The incidence of systemic amyloidosis varies by subtype, geography, and diagnostic era, but all forms share a common challenge: underdiagnosis skews available data toward more severe cases.
Incidence and Prevalence
AL amyloidosis is the most common type, with an annual incidence of 8-12 cases per million population in regions with advanced diagnostic capabilities [88]D5, approximately 10-12 per million person-years in population-based studies [69]B2c. A US claims analysis reported a stable incidence of 9.7 to 14.0 cases per million person-years between 2007 and 2015, with no statistically significant increase (annual percentage change 3%) [73]B2c. Prevalence, however, rose markedly: from 15.5 per million in 2007 to 40.5 per million in 2015 (annual percentage change 12%, P < 0.001), reflecting improved survival with modern therapies [73]B2c. Extrapolating from these data, at least 12 000 adults in the United States are living with AL amyloidosis [73]B2c.
ATTR amyloidosis, both hereditary (ATTRv) and wild-type (ATTRwt), is increasingly recognized. The English National Amyloidosis Centre reported a minimum incidence of systemic amyloidosis of 0.4 per 100 000 population (≈ 4 per million), with AL accounting for the majority, but noted that the true figure likely exceeds 0.8 per 100 000 [79]B2c. ATTRwt is now diagnosed far more frequently than a decade ago, driven by bone scintigraphy and cardiac MRI [75]D5.
AA amyloidosis incidence has declined in developed countries due to better control of chronic inflammatory conditions, but remains a significant burden in regions with untreated infections and autoimmune diseases.
Demographic Variations
Age at diagnosis peaks at 60-79 years [79]B2c; median age in a Queensland cohort was 66 years [69]B2c. Male sex predominates in ATTRwt (≈90% male) and in AL-type cohorts; US mortality data show higher age-adjusted mortality rates in men than women (rate ratio not available) [87]B2c. African American or Black individuals have the highest co-coded amyloidosis-cardiovascular disease mortality (AAMR 11.40 per million), followed by White (5.11) and Hispanic (3.86) individuals [87]B2c. Geographic disparities exist: the Northeast US region had the highest rates (6.71 per million), and metropolitan areas had higher rates than non-metropolitan areas (5.73 vs 4.76) [87]B2c.
Temporal Trends
Mortality co-coded with amyloidosis and cardiovascular disease increased from 4.40 per million in 1999 to 9.31 per million in 2020 (average annual percentage change 3.49%, P < 0.001), with the sharpest rise from 2018-2020 (APC 13.60%) [87]B2c. This likely reflects improved diagnostic recognition, not a true epidemic. In a Korean nationwide cohort, the incidence and prevalence of amyloidosis also increased steadily, with a marked rise after 2019 [84]B2b.
Risk Factors
MGUS is the most important precursor of AL amyloidosis. Among patients with MGUS, those with an abnormal serum free light chain ratio, non-IgG MGUS, and M-protein ≥15 g/L have a 20-year progression risk to myeloma or AL of 58% (all three risk factors) vs 5% (none) [78]D5. The rate of progression specifically to AL amyloidosis at 20 years is 21% in patients whose monoclonal light chain is N-glycosylated (detectable by MASS-FIX), compared with 3% in those without glycosylation (HR not provided; 95% CI 0.0%-38% vs 0.6%-5.5%) [82]B2b.
Mendelian randomization studies implicate elevated monocyte counts (P = 3.8 × 10⁻⁴) and TNFRSF17 gene variants (P = 3.4 × 10⁻⁵) as genetically predicted risk factors for AL amyloidosis, suggesting a causal role of monocyte-driven clone selection and lymphocyte biology [33]B3b.
For ATTR amyloidosis, age and male sex are the dominant risk factors for wild-type disease; hereditary ATTRv is linked to pathogenic TTR gene variants (most commonly V30M in endemic areas such as Portugal, Sweden, Japan).
AA amyloidosis risk is driven by chronic inflammatory states: rheumatoid arthritis, inflammatory bowel disease, familial Mediterranean fever, and chronic infections. The incidence of AA has fallen in settings where biologic therapies effectively suppress SAA levels.
| Risk Factor | Odds Ratio / Relative Risk | Evidence Level |
|---|---|---|
| MGUS (any) | Baseline risk ≈1%/yr progression to AL [78]D5 | 2c (population-based cohort) |
| N-glycosylated monoclonal light chain | 20-yr progression to AL: 21% vs 3% (absolute difference) [82]B2b | 2b (prospective cohort) |
| Elevated monocyte count (genetically predicted) | P = 3.8 × 10⁻⁴ (MR analysis) [33]B3b | 3b (Mendelian randomization) |
| TNFRSF17 variants | P = 3.4 × 10⁻⁵ [33]B3b | 3b (MR) |
| Male sex, age >60 yr | Higher incidence in ATTRwt and AL [87]B2c | 2c (mortality registry) |
| African American ethnicity | AAMR 11.40 vs 5.11 (White) [87]B2c | 2c (death certificate) |
Special Considerations
Cardiac involvement, present in 60-75% of AL and increasingly in ATTR, is itself a risk factor for both thromboembolic events and bleeding, independent of [51]D5. In a Korean cohort, cardiac involvement was associated with an HR 1.396 for all-cause death and HR 1.879 for cardiovascular death [84]B2b.
Waldenström macroglobulinemia carries a 15-year cumulative incidence of amyloidosis-related nephropathy of 5.1% [80]B3b.
Post-infection or vaccine-related triggers are not established for AL or ATTR, although AA amyloidosis classically follows prolonged inflammatory stimuli.
Pearl: In any patient aged >50 years with unexplained nephrotic syndrome, restrictive cardiomyopathy, or , check for a monoclonal gammopathy. The pretest probability is highest in African American men, those with a preceding MGUS with an abnormal free light chain ratio, and those whose M-protein shows N-glycosylation on MASS-FIX, findings that can prompt earlier tissue diagnosis and improve outcomes.
4. Clinical Presentation
- ▸Clinical presentation in amyloidosis is dictated by the precursor protein and organ tropism; symptoms are often non-specific and diagnosed late.
- ▸Red flags for AL include unexplained weight loss, early satiety, and periorbital purpura; for ATTRwt, carpal tunnel syndrome years before cardiac symptoms.
- ▸Autonomic dysfunction (orthostatic hypotension, GI dysmotility) is common but frequently under-recognized and requires specific testing.
From these risk factors emerges a highly variable clinical picture, one that is a direct consequence of which organ bears the brunt of fibril deposition and which precursor protein is involved. Symptoms are often insidious, non-specific, and recognized late, contributing to the diagnostic delay that remains the single greatest barrier to effective therapy [104]D5.
Presenting Symptoms
Cardiac involvement dominates AL and ATTRwt amyloidosis. Shortness of breath and fatigue are the earliest symptoms in AL, whereas often precedes ATTRwt cardiac disease by years [101]D5. Weight loss, unexplained abdominal pain, and early satiety are frequently overlooked red flags for AL [101]D5. In ATTRv (hereditary transthyretin), a painful length-dependent sensory neuropathy is the hallmark, contrasting with the sensory loss predominant in AL [101]D5. Autonomic dysfunction, orthostatic hypotension, , and dysmotility, is common and often under-recognized [103]B3b.
Renal presentation is typically nephrotic-range proteinuria, edema, and progressive kidney dysfunction, seen more often in AL with non-evaluable serum free light chains (dFLC <5 mg/dL) [110]B3b. Hepatic involvement may cause hepatomegaly but rarely jaundice; splenic rupture is a rare sentinel event [113]C4.
Neurological Examination Findings
Motor examination reveals distal symmetrical weakness in advanced neuropathy. Sensory examination shows length-dependent loss of vibration and proprioception (large fiber) in ATTRv and a mixed pattern in AL. Reflexes are diminished or absent at the ankles. Cranial nerve involvement in ATTRv includes vitreous opacities (36% of patients), dry eye (48.5%), scalloped pupil (35.9%), and glaucoma (18.2%) [60]B2a. Autonomic reflex testing, heart rate variability, tilt-table testing, and sudomotor function, frequently confirms dysmotility-related symptoms even when gastrointestinal biopsies are negative [103]B3b.
Phenotypic Variants
| Variant | Key Features | Approximate Frequency |
|---|---|---|
| AL (light chain) | Cardiac, renal, GI, soft tissue (macroglossia, periorbital purpura), autonomic and | Most common systemic type [92]D5 |
| ATTRwt (wild-type) | Carpal tunnel syndrome > arrhythmias > heart failure with preserved ejection fraction; older men > women [111]B3b | Increasingly recognized; ~25% of elderly with HFpEF [36]D5 |
| ATTRv (hereditary) | Painful length-dependent neuropathy, autonomic dysfunction, cardiomyopathy, vitreous opacities; early onset (e.g., G47R mutation) [65]C4 | Depends on mutation prevalence |
| AA (secondary) | Renal dysfunction predominant; proteinuria, nephrotic syndrome; correlates with serum amyloid A concentration [97]B2b | Declining in developed world |
| Hereditary gelsolin (FAF) | Cranial neuropathy, cutis laxa, ophthalmologic abnormalities; renal rarity [63]C4 | Very rare |
Red Flags Requiring Urgent Action
- Orthostatic hypotension with heart failure: signals advanced autonomic and cardiac involvement, needing rapid assessment for hemodynamic instability.
- Non‑traumatic splenic rupture: a sentinel event for AL amyloidosis [113]C4.
- Rapidly progressive proteinuria with or without renal impairment: may herald AA or AL with renal-dominant disease.
- Unexplained weight loss >10% with early satiety: GI-dominant AL [103]B3b.
Atypical Presentations
Isolated GI bleeding without other organ symptoms occurred in 36% of one series, and asymptomatic amyloid was found incidentally on surveillance endoscopy in 7 of 50 systemic AL patients [91]B3b. Ocular-only involvement (vitreous opacities, scalloped pupil) can precede systemic ATTRv by years [60]B2a. Hereditary gelsolin amyloidosis may present with nephrotic syndrome and cranial neuropathy without family history [63]C4. WM-associated AL λ amyloid nephropathy can manifest as rapid-onset nephrotic syndrome with foamy urine and edema [11]C4.
Pearl: The combination of nephrotic-range proteinuria, hepatomegaly, and heart failure with preserved ejection fraction in an older patient should trigger immediate Congo red staining of a fat aspirate or affected organ biopsy, delay measured in weeks worsens survival.
5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
- ▸The diagnostic engine for AL amyloidosis starts with serum FLC, immunofixation, and bone marrow biopsy with Congo red staining and mass spectrometry for typing.
- ▸Flow cytometry detects clonal plasma cells in 99% of patients and can identify circulating plasma cells, which are an independent adverse prognostic factor.
- ▸Cytogenetic testing (FISH for t(11;14) and MYD88 L265P for IgM cases) is essential for risk stratification and treatment selection.
The clinical presentation raises suspicion for systemic amyloidosis; the diagnosis is confirmed and typed through a unified hematology engine that combines serum studies, bone marrow examination, flow cytometry, and cytogenetic/molecular profiling. The goal is to identify the clonal light chain, quantify the clone, and exclude non-AL types.
Serum and Urine Studies: Screening and Quantification
The initial screen for monoclonal gammopathy in suspected AL amyloidosis is a three-test panel: serum immunofixation, urine immunofixation, and serum free light chain (FLC) assay [129]A1c. The FLC assay detects the involved isotype (kappa or lambda) and the difference between involved and uninvolved light chains (dFLC). In a series of 133 untreated AL patients, the combination of serum and urine immunofixation plus FLC detected the monoclonal gammopathy in 92% of cases [118]B3b. The FLC test alone detected 87%, but the two modalities are complementary [118]B3b. The dFLC is a key biomarker: a dFLC ≥ 18 mg/dL is part of the Mayo 2012 staging system, though its prognostic value may be diminished in the era of -based therapy [4]B2b[130]B2b. In patients with IgM-related amyloidosis, a significant proportion (approximately 34%) have a non-evaluable dFLC, and the serum IgM level and immunofixation are critical [127]B2b.
Bone Marrow Aspirate and Biopsy: The Gold Standard Tissue
A bone marrow biopsy is recommended in all patients with suspected AL amyloidosis, combined with a subcutaneous fat pad aspiration to maximise diagnostic yield [129]A1c. The marrow is examined for:
- Plasma cell percentage: The median bone marrow plasma cell (BMPC) burden in AL is approximately 10-15%. A BMPC ≥ 20% defines a higher-risk subgroup with features overlapping with , more frequent lytic bone lesions, , and intact immunoglobulin secretion, and a median overall survival of 12 months compared with 33 months for 5-19% and 81 months for <5% BMPCs [141]B2b.
- Congo red staining: Amyloid deposits appear as apple-green birefringence under polarised light. Positive staining is diagnostic for amyloid, but typing requires immunohistochemistry or mass spectrometry.
- Mass spectrometry-based proteomics: Laser capture microdissection followed by mass spectrometry (LC-MS/MS) is the gold standard for amyloid typing. In a clinical series of 366 fat pad aspirates, LC-MS/MS had a sensitivity of 90% and identified the specific precursor protein in 74% (AL), 13% (ATTR), and 1% (AA) [41]B3b. This approach also identifies clonotypic immunoglobulin variable gene usage and variant peptides in hereditary amyloidosis [41]B3b.
Flow Cytometry: Quantifying the Clonal Plasma Cell
Multiparametric flow cytometry (MFC) on bone marrow aspirates detects clonal plasma cells in virtually all AL patients (99%) [8]B2b. MFC identifies the clonal population by abnormal expression of CD19, CD56, CD45, and CD138. In AL, the clonal plasma cell compartment is often smaller than in multiple myeloma, but a predominantly clonal PC compartment in the absence of a myeloma-like tumour expansion is a hallmark [8]B2b. MFC can also detect circulating plasma cells (cPCs) in the peripheral blood: in one study, cPCs were present in 42% of 154 AL patients and were independently associated with inferior overall survival (90 vs. 98 months, p=0.003) [58]B2b. The presence of cPCs worsens prognosis, but achieving a very good partial response (VGPR) or better can overcome this adverse impact [58]B2b. Minimal residual disease (MRD) assessment by MFC after therapy is emerging: in 65 patients in hematologic complete response, 55% had residual clonal plasma cells by MFC, and MRD-negative patients had a trend toward higher organ response rates (90% vs. 75%) [19]C4.
Cytogenetic and Molecular Profiling
Interphase fluorescence in situ hybridization (FISH) with cytoplasmic immunoglobulin staining (cIg-FISH) on bone marrow plasma cells is standard. The most common abnormality is t(11;14)(q13;q32), present in 39-50% of AL patients [42]B2b. t(11;14) is associated with lower BMPC burden but independently predicts inferior survival (hazard ratio 2.1, 95%) [42]B2b. Other recurrent abnormalities include trisomies, del(13q), and del(17p) (though less common than in myeloma). High-risk cytogenetic abnormalities (HRCA) defined as del(17p), t(4;14), t(14;16), t(14;20) are associated with lower cardiac response rates [39]B2b.
For IgM-related AL amyloidosis, the underlying clone is often a lymphoplasmacytic lymphoma (LPL) rather than a pure plasma cell neoplasm (PPCN). In a study of 75 IgM AL patients, 63% had LPL and 23% had PPCN [54]B2b. The MYD88 L265P mutation is present in 84% of LPL cases but absent in PPCN, while t(11;14) is present in 60% of PPCN and absent in LPL [54]B2b. Testing for MYD88 L265P on bone marrow or peripheral blood is therefore recommended to guide therapy, LPL is treated with -based regimens (e.g., bendamustine-rituximab), while PPCN is treated with anti-plasma cell therapy (e.g., daratumumab- -bortezomib- ) [140]A1c[62]C4.
| Table 1. Key Cytogenetic/Molecular Abnormalities in AL Amyloidosis | ||
|---|---|---|
| Abnormality | Frequency | Clinical Significance |
| t(11;14)(q13;q32) | 39-50% | Adverse prognosis; lower BMPC; targetable with BCL-2 inhibitors (venetoclax) [42]B2b |
| del(13q) | 30% | Associated with higher BMPC burden [42]B2b |
| del(17p) | <5% | Poor prognosis; therapy resistance [39]B2b |
| MYD88 L265P | 58% in IgM AL | Distinguishes LPL from PPCN; predicts rituximab sensitivity [54]B2b |
Pearl: In a patient with suspected AL amyloidosis, a non-diagnostic fat pad aspirate should not delay a bone marrow biopsy with Congo red staining and mass spectrometry; the combination of marrow and fat pad sampling has a sensitivity approaching 90% for systemic amyloidosis [129]A1c.
Controversies and Guideline Disagreement
| Question | Position A (ASH 2026) | Position B (BSH 2026) | Strength | Implication |
|---|---|---|---|---|
| Role of endomyocardial biopsy for | ASH guidelines recommend against routine endomyocardial biopsy if non-invasive studies (NT-proBNP, echocardiography, MRI) are diagnostic [129]A1c | BSH guidelines note that endomyocardial biopsy is the gold standard but may be reserved for cases where non-invasive testing is inconclusive [114]A1c | Conditional | In practice, most patients with suspected cardiac AL can be diagnosed without endomyocardial biopsy if NT-proBNP is elevated and echocardiography is abnormal [117]B3b |
| Use of mass spectrometry vs. immunohistochemistry for typing | ASH recommends mass spectrometry as the preferred method for amyloid typing [129]A1c | BSH guidelines accept immunohistochemistry if performed with a panel of antibodies and validated controls [115]A1c | Strong | Mass spectrometry is superior for typing rare subtypes and for detecting mixed amyloid deposits [41]B3b |
6. Staging, Risk Stratification & Prognostic Scoring
- ▸Cardiac biomarker staging (Mayo 2004, 2012, AL-ISS) is the primary determinant of prognosis in AL amyloidosis.
- ▸Cytogenetic abnormalities (especially +1q) and bone marrow plasma cell burden >10% provide independent prognostic information.
- ▸Restaging after treatment initiation is prognostic; stage migration predicts worse survival.
With the diagnosis of AL amyloidosis confirmed, risk stratification using validated staging systems determines prognosis and guides treatment intensity. The heart is the dominant prognostic organ, and cardiac biomarker-based staging remains the cornerstone of risk assessment.
Cardiac Staging Systems
Three widely used systems stratify patients by cardiac biomarkers. The Mayo 2004 system (subsequently modified to add stage IIIb) uses NT-proBNP and cardiac troponin T (cTnT) thresholds. The Mayo 2012 system incorporates the difference between involved and uninvolved free light chains (dFLC ≥18 mg/dL), improving discrimination [4]B2b. The AL International Staging System (AL-ISS), validated in the era, adds echocardiographic global longitudinal strain (GLS) to cardiac biomarkers, defining an ultra-poor risk stage IIIC (1-year OS 53% despite daratumumab) [156]B2b. Each system is listed in Table 1. The Mayo3b staging system performs most robustly in patients with renal impairment or atrial arrhythmia [161]B2b.
| Staging system | Components | Stages | Median OS (months) |
|---|---|---|---|
| Mayo 2004 (modified) | NT-proBNP, cTnT | I, II, IIIa, IIIb | NR, 10.8, 4.6, 1.1 (at 3-month restaging) [133]B2b |
| Mayo 2012 | dFLC ≥18 mg/dL, cTnT ≥0.025 ng/mL, NT-proBNP ≥1800 pg/mL | I-IV | 94.1, 40.3, 14, 5.8 [4]B2b |
| AL-ISS | NT-proBNP (332, 8500 ng/L), hs-TnT ≥50 ng/L, GLS ≥-9% | I, II, IIIa, IIIb, IIIC | NR, NR, 67, 26, 7 [156]B2b |
Cytogenetics, Plasma Cell Burden, and Clonal Factors
Cytogenetic abnormalities add independent prognostic information. Gain 1q21 (+1q) is associated with lower hematologic complete response (30% vs 48%) and worse event-free survival (HR 2.06) in daratumumab-treated patients [72]B2b. t(11;14) (present in ~50% of patients) predicts inferior response to bortezomib-based therapy but not to daratumumab or stem cell transplant [167]B2b. Bone marrow plasma cell (BMPC) burden ≥10% defines AL with and confers a median OS of 16.2 months vs 46 months for AL alone [30]B2b; BMPC ≥20% is independently adverse [141]B2b. The plasma cell proliferative index (PCPI) >0.5% predicts worse overall survival after transplant (HR 1.5) [163]B2b.
Restaging and Response Assessment
Staging systems retain prognostic value when applied at 3 and 6 months after treatment initiation. Stage migration to a higher stage predicts significantly worse survival [133]B2b. At second-line therapy, Mayo 2012 staging remains prognostic (risk ratio 3.03 for >stage 2) [168]B2b. High-risk dFLC progression (dFLC >20 mg/L, >20% of baseline, and >50% increase from best response) should trigger rescue therapy before cardiac progression occurs [154]B2b.
Emerging Biomarkers
Novel biomarkers may refine existing models. Heart-type fatty acid binding protein (H-FABP) >9.5 ng/mL adds independent prognostic value to Mayo 2012 (C-index increase from 0.611 to 0.660) [170]B2b. Von Willebrand factor antigen (VWF:Ag) ≥230 U/dL identifies very high-risk subgroups within Mayo stage III [149]B2b. Myocardial work indices (global work index ≤840 mmHg%) improve risk discrimination beyond traditional models [165]B2b. In the daratumumab era, the prognostic value of dFLC ≥180 mg/L may be diminishing [130]B2b, underscoring the need for updated, therapy-specific models.
Pearl: The Mayo 2012 and AL-ISS staging systems are the cornerstones of risk stratification; stage migration at 3 months carries prognostic significance equal to baseline stage, and restaging should be routine after treatment initiation [133]B2b.
7. Acute & Emergency Management
- ▸Acute cardiac emergencies in AL amyloidosis include decompensated HFpEF, arrhythmias, and cardiac tamponade; bedside echocardiography is essential for rapid diagnosis.
- ▸Hyperfibrinolysis is the dominant cause of bleeding in AL amyloidosis; tranexamic acid is first-line therapy (1 g IV every 8 hours, dose-adjusted for renal function).
- ▸Delayed diagnosis of AL amyloidosis doubles the odds of CV-related emergency department visits (adjusted OR 1.98) [178].
From the risk stratification and staging framework established in the previous section, this section addresses the acute, life-threatening complications that can arise in AL amyloidosis, particularly cardiac decompensation, arrhythmias, pericardial effusion/tamponade, and bleeding due to hyperfibrinolysis. Timely recognition and of these emergencies are critical, as delayed diagnosis has been shown to double the odds of cardiovascular-related emergency room visits (adjusted OR 1.98, 95% CI 1.21-3.24) [178]B3b (3b).
Step 1: Initial Assessment and Severity Classification
In any patient with known or suspected AL amyloidosis presenting with acute dyspnea, hypotension, syncope, or bleeding, the first priority is to identify the emergency subtype:
- Cardiac decompensation: Look for signs of (jugular venous distension, peripheral edema, pulmonary crackles), hypotension, and arrhythmia. typically presents with (HFpEF) and restrictive physiology; bedside echocardiography is essential to assess left ventricular wall thickness, diastolic function, and pericardial effusion [180]D5 (5).
- Cardiac tamponade: Pericardial effusion can occur in cardiac amyloidosis; a large effusion with hemodynamic compromise requires urgent pericardiocentesis [177]D5 (5).
- Bleeding: AL amyloidosis is associated with hyperfibrinolysis, which increases the risk of spontaneous or procedure-related bleeding [174]B2a (2a). Check coagulation profile, fibrinogen, D-dimer, and consider thromboelastography. Patients may present with ecchymoses, prolonged bleeding after venipuncture, or overt hemorrhage.
Disposition: Patients with any hemodynamic instability, acute heart failure, tamponade, or active bleeding should be admitted to an intensive care unit (ICU) or coronary care unit. Those with mild decompensation (e.g., stable heart failure with preserved EF, no arrhythmia) may be managed on a telemetry ward.
Step 2: Cardiac Emergency Management
Acute decompensated HFpEF: Loop diuretics (e.g., IV 20-40 mg, repeated until euvolemia) are first-line, but use cautiously because of restrictive physiology, excessive preload reduction can precipitate hypotension. Inotropic support (e.g., or ) is reserved for . Avoid beta-blockers in the acute setting if the patient is hypotensive; rate control for can be achieved with (IV 150 mg over 10 min, then 1 mg/min for 6 h, then 0.5 mg/min) [label] (5).
Cardiac tamponade: Perform urgent pericardiocentesis under echocardiographic guidance. Remove fluid slowly to avoid rapid re-expansion; drain completely if possible. Send pericardial fluid for cytology, culture, and Congo red staining if amyloid is not already confirmed.
Arrhythmia management: Atrial fibrillation is common. Anticoagulation is controversial because of the high bleeding risk (see Controversies below). For rhythm control, amiodarone is the preferred antiarrhythmic because it has minimal negative inotropic effect. Avoid in cardiac amyloidosis due to increased risk of toxicity.
Step 3: Bleeding Emergency Management
Hyperfibrinolysis: The primary mechanism of bleeding in AL amyloidosis is hyperfibrinolysis, not thrombocytopenia or coagulopathy [174]B2a (2a). First-line therapy is tranexamic acid (TXA) 1 g IV every 8 hours (reduce dose if eGFR <30 mL/min) [label] (5). Antifibrinolytic therapy should be started as soon as bleeding is recognized and continued until the acute episode resolves. If hypofibrinogenemia is present (<150 mg/dL), consider cryoprecipitate infusion (10-15 units) to raise fibrinogen levels.
Peri-procedural prophylaxis: For patients with AL amyloidosis undergoing invasive procedures (e.g., bone marrow biopsy, central line placement), administer TXA 1 g IV pre-procedure, then 1 g IV every 8 hours for 24 hours post-procedure [174]B2a (5).
What NOT to do: Do not use fresh frozen plasma (FFP) unless there is documented coagulopathy (e.g., PT/INR >1.5) because FFP does not correct hyperfibrinolysis and can worsen volume overload. Do not give platelet transfusions for bleeding unless platelet count <30,000/μL.
Step 4: Monitoring and Titration
- Cardiac: Continuous ECG telemetry for arrhythmia detection. Daily weight, input/output, and BNP or NT-proBNP to guide diuresis. Repeat echocardiography if tamponade was present or if clinical status deteriorates.
- Bleeding: Monitor fibrinogen, D-dimer, and platelet count daily. If bleeding continues despite TXA, re-evaluate for other causes (e.g., coagulopathy, platelet dysfunction, surgical source).
- Renal function: Acute kidney injury from nephrotic syndrome or progression of renal amyloidosis can occur; monitor creatinine and urine output.
Step 5: Resolution and Transition to Definitive Therapy
Once the acute emergency is stabilized (e.g., heart failure compensated, tamponade drained, bleeding controlled), the patient should be transitioned to long-term disease-directed therapy (see Section 8: Long-term & Definitive Management). The underlying AL amyloidosis must be treated with chemotherapy (e.g., -based regimens) to prevent recurrent crises. The presence of acute emergencies does not preclude eventual chemotherapy, but organ function must be optimized first.
Pearl: In AL amyloidosis with acute bleeding, hyperfibrinolysis is the dominant mechanism; administer tranexamic acid 1 g IV every 8 hours (adjusted for renal function) as first-line therapy (PMID 34058766) [174]B2a (2a).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Anticoagulation for atrial fibrillation in cardiac amyloidosis | AHA/ACC 2022, no specific recommendation beyond standard CHA₂DS₂-VASc score; balances bleeding risk | ESC 2021, suggests caution because of increased bleeding risk; individualize decision | Moderate (both guidelines note the lack of evidence) | Most clinicians avoid anticoagulation unless bleeding risk is low and CHA₂DS₂-VASc ≥2; the decision is shared with the patient. |
No major guideline disagreements identified for the management of hyperfibrinolysis or acute decompensated HFpEF in amyloidosis.
| Drug | Indication | Dose | Target / Max dose | Renal adjustment | Key monitoring |
|---|---|---|---|---|---|
| Acute bleeding (hyperfibrinolysis) | 1 g IV every 8 hours | 1 g IV every 8 hours; max 3 g/day | eGFR <30 mL/min: 0.5 g IV every 8 hours | Fibrinogen, D-dimer, bleeding time | |
| Cryoprecipitate | Hypofibrinogenemia (<150 mg/dL) | 10-15 units IV | Titrate to fibrinogen >150 mg/dL | No adjustment | Fibrinogen level |
8. Long-term & Definitive Management
- ▸Daratumumab plus CyBorD is the new standard of first-line therapy for AL amyloidosis, achieving 53% CR and reducing organ deterioration by 42% (ANDROMEDA trial) [15].
- ▸For ATTR cardiomyopathy, vutrisiran 25 mg SC every 12 weeks reduces mortality and cardiovascular events and preserves functional capacity (HELIOS-B) [66].
- ▸In AA amyloidosis, aggressive suppression of SAA to <10 mg/L is the primary therapeutic goal; eprodisate may slow renal decline but is not widely available [97][68].
The acute stabilization of arrhythmias, volume status, and coagulopathy described in the previous section must be followed immediately by disease-directed therapy aimed at suppressing the precursor protein, the only intervention proven to halt organ damage and improve survival. The choice of regimen, dose intensity, and monitoring frequency depend on the amyloidosis type, the severity of cardiac involvement, and the clonal characteristics of the underlying plasma cell or B-cell disorder.
Step 1: Risk Stratification and Treatment Goal
Before selecting therapy, classify the patient by amyloidosis type (AL, ATTR, AA) and assess cardiac stage. For AL amyloidosis, the Mayo 2012 staging system uses NT‑proBNP ≥ 1800 pg/mL, cardiac troponin T ≥ 0.025 ng/mL, and difference between involved and uninvolved free light chains (dFLC) ≥ 18 mg/dL to assign stages I-IV, with median overall survival ranging from 94.1 months (stage I) to 5.8 months (stage IV) [4]B2b. Stage IIIb, defined by NT‑proBNP > 8500 ng/L, identifies patients at highest early mortality risk and requires the most urgent, effective therapy [131]B2b[214]B2b. The treatment goal is to achieve a hematologic response of very good partial response (VGPR) or better within 3 months, because a VGPR at 1 month is associated with a median OS of 47 months versus 5 months in non‑responders [131]B2b. For ATTR amyloidosis, functional capacity ( , 6‑minute walk distance) and cardiac biomarkers guide therapy, with the goal of preserving functional capacity and reducing mortality [66]A1b[184]A1b. For AA amyloidosis, the critical therapeutic target is the serum amyloid A (SAA) concentration: keeping the median SAA < 10 mg/L during follow‑up is associated with amyloid regression in 60 % of patients and superior survival [97]B2b.
Step 2: First‑Line Therapy
AL amyloidosis. The combination of , , bortezomib, and (Dara‑CyBorD) is now the standard of care. In the phase 3 ANDROMEDA trial, 388 patients with newly diagnosed AL amyloidosis were randomized to Dara‑CyBorD or CyBorD alone. The hematologic complete response rate was 53 % vs. 18 % (relative risk ratio 2.9; 95 % CI 2.1 to 4.1; P < 0.001), and survival free from major organ deterioration or hematologic progression favored the daratumumab group (HR 0.58; 95 % CI 0.36 to 0.93; P = 0.02) [15]A1b. Daratumumab is administered subcutaneously (1,800 mg) or intravenously (16 mg/kg) weekly in cycles 1-2, every 2 weeks in cycles 3-6, and then every 4 weeks for up to 2 years. CyBorD is given weekly for 6 cycles: bortezomib 1.3 mg/m² subcutaneously, cyclophosphamide 300 mg/m² orally or intravenously, and dexamethasone 40 mg orally or intravenously, all on days 1, 8, 15, 22 of a 28‑day cycle [182]C4[15]A1b. For patients with Mayo stage IIIb disease, who were excluded from ANDROMEDA, retrospective data demonstrate that upfront daratumumab‑based therapy yields a median OS not reached at 14.5 months versus 6.6 months with bortezomib alone (P = 0.002) [214]B2b. The oral proteasome inhibitor ixazomib (4 mg days 1, 8, 15) plus dexamethasone (20 mg days 1, 8, 15, 22) in 28‑day cycles is an alternative for patients who cannot tolerate injectable therapy, but the overall hematologic response rate in relapsed/refractory AL was only 53 % [198]A1b.
ATTR amyloidosis. For patients with ATTR‑cardiomyopathy (ATTR‑CM), the RNA interference agent vutrisiran is approved. In the HELIOS‑B trial, 655 patients were randomized to vutrisiran 25 mg subcutaneously every 12 weeks or placebo. Vutrisiran reduced the risk of death from any cause and recurrent cardiovascular events (HR 0.72; 95 % CI 0.56 to 0.93; P = 0.01), and improved the 6‑minute walk distance (least‑squares mean difference 26.5 m; 95 % CI 13.4 to 39.6; P < 0.001) and quality‑of‑life (KCCQ‑OS difference 5.8 points; 95 % CI 2.4 to 9.2; P < 0.001) [66]A1b. Patisiran (0.3 mg/kg intravenously every 3 weeks) also preserved functional capacity in ATTR‑CM (APOLLO‑B: median 6‑minute walk difference 14.69 m; 95 % CI 0.69 to 28.69; P = 0.02) [184]A1b. For hereditary ATTR with polyneuropathy, inotersen 300 mg subcutaneously weekly improved the mNIS + 7 (difference ‑19.7 points; 95 % CI ‑26.4 to ‑13.0; P < 0.001) [16]A1b. Tafamidis, a TTR stabilizer, reduces all‑cause mortality in octogenarian patients with ATTR‑CM (HR 0.51; 95 % CI 0.40 to 0.67; P < 0.01) [221]A1a. Gene‑editing with nexiguran ziclumeran (CRISPR‑Cas9) is in early trials, showing a sustained 90 % reduction in serum TTR at 12 months after a single infusion [190]C4[191]C4.
AA amyloidosis. The cornerstone is aggressive control of the underlying chronic inflammatory condition to suppress SAA production. Median survival after diagnosis is 133 months, and the risk of death is 17.7 times higher with SAA ≥ 155 mg/L versus < 4 mg/L [97]B2b. Eprodisate, a glycosaminoglycan mimetic that inhibits amyloid polymerization, slowed the decline in creatinine clearance (10.9 vs. 15.6 mL/min/1.73 m² per year; P = 0.02) in a phase 3 trial, but it is not widely available [68]A1b.
Step 3: Monitoring and Response Assessment
AL amyloidosis. Hematologic response should be assessed after each cycle using serum free light chains (dFLC) and serum/urine immunofixation. The validated response categories are: complete response (CR), normal FLC ratio and negative immunofixation; VGPR, dFLC < 40 mg/L; partial response (PR), dFLC decrease > 50 % [155]B2b. Cardiac response is defined by a > 30 % and > 300 ng/L decrease in NT‑proBNP (or a > 50 % decrease from an elevated baseline) [124]B3b[155]B2b. Graded cardiac response criteria (cardiac CR, VGPR, PR, NR) better predict survival: 5‑year OS rates are 93 %, 79 %, 65 %, and 33 %, respectively [124]B3b. Renal response is defined by a ≥ 30 % reduction in proteinuria (or normalization to < 0.5 g/day) in the absence of worsening renal function [134]B2b. Re‑staging at 3 and 6 months using the Mayo systems provides dynamic prognostic information; stage migration to a higher stage portends worse survival [133]B2b.
ATTR amyloidosis. Monitor with serial NT‑proBNP, troponin, 6‑minute walk distance, and KCCQ‑OS. In HELIOS‑B, NT‑proBNP and troponin I ratios at 12 months were 0.68 in the vutrisiran group [222]D5.
AA amyloidosis. Monitor SAA levels monthly until controlled, then every 3-6 months. Measure proteinuria, serum creatinine, and eGFR to track renal function.
Step 4: Escalation and Second‑Line Therapy
AL amyloidosis. If the patient fails to achieve at least a PR after 2-3 cycles, or if organ deterioration occurs, switch therapy. Options include: (1) a bortezomib‑based regimen if not used upfront (e.g., bortezomib‑melphalan‑dexamethasone, which improved OS vs. melphalan‑dexamethasone with HR 0.50; 95 % CI 0.27 to 0.90) [186]A1b; (2) lenalidomide‑based combinations (e.g., bortezomib‑lenalidomide‑dexamethasone, but with higher toxicity) [211]C4; (3) daratumumab‑based therapy if not used in first line; or (4) BCMA‑directed immunotherapies. A meta‑analysis of BCMA‑directed bispecific antibodies (teclistamab, elranatamab) in relapsed/refractory AL reported a pooled hematologic overall response rate of 91 % (95 % CI 87 %‑93 %) and a complete response rate of 64 % (95 % CI 42 %‑82 %), with cardiac and renal response rates of 59 % and 34 %, respectively [85]A1a. In a phase 2 trial of elranatamab monotherapy, 9 patients with advanced AL achieved 100 % overall response and 67 % complete response [202]D5. Anti‑BCMA chimeric antigen receptor T‑cell therapy (HBI0101) in 16 heavily pretreated patients produced a 94 % overall response rate and 75 % CR, but median OS was only 10.1 months, largely due to advanced cardiac disease at baseline [193]C4. Isatuximab monotherapy (20 mg/kg weekly cycle 1, then every 2 weeks) in relapsed AL yielded a 77 % hematologic response rate with 57 % ≥VGPR [188]C4. The anti‑fibril antibody anselamimab, when added to anti‑plasma cell therapy, did not meet its primary endpoint in the overall population but significantly improved all‑cause mortality and cardiovascular hospitalizations in patients with κ‑isotype AL (HR for ACM 0.38; 95 % CI 0.17 to 0.86) [187]A1b.
ATTR amyloidosis. No established second‑line agents exist. Switching between RNAi therapies (vutrisiran, patisiran) or from tafamidis to an RNAi agent may be considered, though data are limited. Gene‑editing with nexiguran ziclumeran is being investigated in phase 3 trials [190]C4[191]C4.
AA amyloidosis. If SAA remains elevated, escalate anti‑inflammatory therapy (e.g., biologic agents targeting IL‑1, IL‑6, or TNF‑α) as indicated by the underlying disease.
What NOT to Do
- Do not use high‑dose melphalan plus autologous stem cell transplantation (ASCT) as first‑line therapy in unselected patients. The randomized trial comparing ASCT with standard‑dose melphalan‑dexamethasone showed no survival benefit (median OS 22.2 vs. 56.9 months; P = 0.04 favoring the non‑transplant arm) [185]A1b. While ASCT remains an option for highly selected patients with good performance status and limited cardiac involvement, its utilization has declined with the advent of daratumumab‑based regimens [128]B2b[204]D5.
- Do not continue dexamethasone 40 mg weekly for more than 6 months in AL amyloidosis; prolonged use predisposes to volume overload, infections, and cataracts without added benefit [207]D5.
- Do not use bortezomib in patients with class III or IV heart failure without careful dose adjustment and close monitoring, as it can exacerbate cardiac dysfunction [199]C4[206]B3b.
- Do not rely on the Mayo 2012 staging system to predict prognosis in patients treated with modern daratumumab‑based regimens; a high dFLC > 180 mg/L no longer carries independent prognostic significance in this setting [130]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Role of ASCT in first‑line AL amyloidosis | EMN recommendations (2020), ASCT is a first‑line option for eligible patients with good performance status and limited cardiac involvement [140]A1c | Many experts (2023-2025), ASCT should be reserved for suboptimal response to Dara‑CyBorD or relapsed disease, given the high efficacy of modern therapy and declining ASCT utilization [128]B2b[204]D5 | Moderate (no randomized controlled trial comparing Dara‑CyBorD vs. ASCT) | Most centers now use a response‑driven approach: start Dara‑CyBorD and proceed to ASCT only if inadequate response is seen [212]C4 |
| Optimal dexamethasone dose in AL amyloidosis | Traditional regimens, 40 mg once weekly for 6 months or more [15]A1b | Corticosteroid‑sparing strategies, reduce to 20 mg weekly or discontinue after 1-2 cycles in frail patients, with evidence that lower doses maintain efficacy with less toxicity [207]D5 | Moderate (based on extrapolation from myeloma trials and expert opinion) | Individualize: younger, fit patients may tolerate full dose; older or frail patients should receive reduced doses to avoid volume overload and infections |
Drug / Modality Comparison Table
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Dara‑CyBorD | AL, first‑line | Dara 1800 mg SC weekly×2, then q2wk×4, then q4wk; CyBorD weekly×6 | ANDROMEDA [15]A1b | CR 53 % vs. 18 %; organ deterioration HR 0.58; 95 % CI 0.36‑0.93 | 1b |
| BMDex | AL, first‑line (alternative) | Bortezomib 1.3 mg/m² SC, melphalan 0.25 mg/kg, dex 40 mg, days 1‑4 every 28d | Kastritis 2020 [186]A1b | VGPR/CR 64 % vs. 39 %; OS HR 0.50; 95 % CI 0.27‑0.90 | 1b |
| Vutrisiran | ATTR‑CM, first‑line | 25 mg SC every 12 weeks | HELIOS‑B [66]A1b | ACM/cardiovascular events HR 0.72; 95 % CI 0.56‑0.93; 6MWD +26.5 m | 1b |
| Patisiran | ATTR‑CM, first‑line | 0.3 mg/kg IV every 3 weeks | APOLLO‑B [184]A1b | 6MWD median +14.7 m; KCCQ‑OS +3.7 points | 1b |
| Inotersen | ATTRv‑PN, first‑line | 300 mg SC weekly | NEURO‑TTR [16]A1b | mNIS+7 ‑19.7 points; QoL ‑11.7 points | 1b |
| Tafamidis | ATTR‑CM, octogenarians | Not specified in refs | Meta‑analysis [221]A1a | All‑cause mortality HR 0.51; 95 % CI 0.40‑0.67 | 1a |
| BCMA BsAbs | R/R AL | Teclistamab/elranatamab per label | Meta‑analysis [85]A1a | ORR 91 %; CR 64 %; cardiac response 59 % | 1a |
| Anti‑BCMA CAR‑T | R/R AL | 800 × 10⁶ CARTs | HBI0101 [193]C4 | ORR 94 %; CR 75 %; median OS 10.1 mo | 4 |
Dosing Table
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Daratumumab (SC) | 1,800 mg SC weekly cycles 1‑2 | 1,800 mg SC q2wk cycles 3‑6, then q4wk | No adjustment | No adjustment | Infusion‑related reactions, cytopenias |
| Bortezomib (SC) | 1.3 mg/m² SC twice weekly | 1.3 mg/m² SC weekly | No adjustment | Child‑Pugh B: 0.7 mg/m² | , cardiac function |
| Cyclophosphamide (PO/IV) | 300 mg/m² PO/IV | 300 mg/m² | CrCl 10‑50: 75 % dose | Monitor for hepatotoxicity | CBC, cystitis prophylaxis |
| Dexamethasone | 40 mg PO/IV weekly | 40 mg weekly for 6 cycles | No adjustment | No adjustment | Volume status, glucose, infections |
| Ixazomib | 4 mg PO days 1, 8, 15 | 4 mg PO | CrCl ≥30: no adjustment | Child‑Pugh B: 3 mg; Child‑Pugh C: avoid | Rash, toxicity |
| Vutrisiran | 25 mg SC every 12 weeks | 25 mg SC every 12 weeks | No adjustment | No adjustment | Infusion‑related reactions, liver enzymes |
| Patisiran | 0.3 mg/kg IV every 3 weeks | 0.3 mg/kg IV | No adjustment | No adjustment | Infusion‑related reactions, arthralgia |
| Inotersen | 300 mg SC weekly | 300 mg SC weekly | No adjustment | Not defined | Platelet count, renal function (glomerulonephritis) |
Pearl: For AL amyloidosis, initiate daratumumab‑CyBorD as soon as the diagnosis is confirmed; a hematologic VGPR by 3 months is the strongest predictor of long‑term survival, and failure to achieve this should prompt an early switch to second‑line therapy (including BCMA‑directed immunotherapies) [15]A1b[131]B2b[85]A1a.
| Regimen | Amyloidosis type | Dose/Route | Key trial | Outcome | Evidence level |
|---|---|---|---|---|---|
| Dara-CyBorD | AL | Dara 1800 mg SC weekly×2 then q2wk×4 then q4wk; CyBorD weekly×6 | ANDROMEDA [15]A1b | CR 53% vs 18%; organ deterioration HR 0.58 | 1b |
| BMDex | AL | Bortezomib 1.3 mg/m² SC, melphalan 0.25 mg/kg, dex 40 mg days 1-4 q28d | Kastritis 2020 [186]A1b | VGPR/CR 64% vs 39%; OS HR 0.50 | 1b |
| Vutrisiran | ATTR-CM | 25 mg SC q12w | HELIOS-B [66]A1b | ACM/cardiovascular events HR 0.72; 6MWD +26.5 m | 1b |
| Patisiran | ATTR-CM | 0.3 mg/kg IV q3w | APOLLO-B [184]A1b | 6MWD median +14.7 m; KCCQ-OS +3.7 points | 1b |
| Inotersen | ATTRv-PN | 300 mg SC weekly | NEURO-TTR [16]A1b | mNIS+7 -19.7 points; QoL -11.7 points | 1b |
| Tafamidis | ATTR-CM (octogenarians) | Dose not specified | Meta-analysis [221]A1a | ACM HR 0.51; 95% CI 0.40-0.67 | 1a |
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Daratumumab (SC) | 1,800 mg SC weekly cycles 1-2 | 1,800 mg SC q2wk cycles 3-6, then q4wk | No adjustment | No adjustment | Infusion reactions, cytopenias |
| Bortezomib (SC) | 1.3 mg/m² SC twice weekly | 1.3 mg/m² SC weekly | No adjustment | Child-Pugh B: 0.7 mg/m² | Peripheral neuropathy, cardiac function |
| Cyclophosphamide (PO/IV) | 300 mg/m² PO/IV | 300 mg/m² | CrCl 10-50: 75% dose | Monitor for hepatotoxicity | CBC, cystitis prophylaxis |
| Dexamethasone | 40 mg PO/IV weekly | 40 mg weekly for 6 cycles | No adjustment | No adjustment | Volume status, glucose, infections |
| Ixazomib | 4 mg PO days 1,8,15 | 4 mg PO | CrCl ≥30: no adjustment | Child-Pugh B: 3 mg; Child-Pugh C: avoid | Rash, GI toxicity |
| Vutrisiran | 25 mg SC every 12 weeks | 25 mg SC every 12 weeks | No adjustment | No adjustment | Infusion reactions, liver enzymes |
| Patisiran | 0.3 mg/kg IV every 3 weeks | 0.3 mg/kg IV | No adjustment | No adjustment | Infusion reactions, arthralgia |
| Inotersen | 300 mg SC weekly | 300 mg SC weekly | No adjustment | Not defined | Platelet count, renal function |
9. Hematopoietic Cell Transplantation & Cellular Therapy
- ▸ASCT in AL amyloidosis has evolved to a risk-adapted strategy with TRM under 3% and median OS >6 years in contemporary cohorts.
- ▸Anti-BCMA CAR-T therapy achieves high hematologic response rates (94%) but early mortality remains high in patients with advanced cardiac disease.
- ▸Allogeneic SCT is rarely used due to high TRM (40%) but may provide durable remissions via graft-versus-amyloidosis effect.
Building on the durable disease control achievable with modern induction regimens, hematopoietic cell transplantation and engineered cellular therapies offer the potential for deeper, more sustained remissions, and in the case of allogeneic transplantation, possible cure, for selected patients with AL amyloidosis.
Autologous Stem Cell Transplantation (ASCT)
ASCT remains a cornerstone of consolidative therapy for AL amyloidosis, though its use has evolved from a universal first-line approach to a risk-adapted strategy. The only randomized trial comparing ASCT with standard-dose chemotherapy, which enrolled only 100 patients, found that ASCT did not improve overall survival (median 22.2 vs 56.9 months; P=0.04 in favor of the non-transplant arm) [185]A1b (1b). However, this trial has been criticized for including high-risk patients and for its high early mortality (14.5% in the ASCT arm).
Contemporary experience from the Mayo Clinic (N=672) and a multicenter European collaboration (N=1047) demonstrates that in carefully selected patients, ASCT yields excellent outcomes. In the Mayo cohort (2010-2016), treatment-related mortality (TRM) dropped to 2.4%, median overall survival was not reached (vs 75 months in the 1996-2002 cohort), and hematologic response rates reached 84% [208]C4 (4). The European multicenter study (2010-2020) reported a Day-100 mortality of 3.0%, with a median overall survival of 6.3 years and post-ASCT deepening of response in 56.3% of patients who had not achieved a complete response with induction [235]B2b (2b).
Patient selection is critical. Independent predictors of inferior survival after ASCT include: age ≥60 years, bone marrow plasma cells ≥20%, pre-ASCT dFLC ≥40 mg/L, elevated cardiac biomarkers (troponin, NT-proBNP), lambda-restricted disease, reduced eGFR, and reduced-dose conditioning [235]B2b (2b). The Mayo 2012 stage system and conditioning dose (melphalan 200 mg/m² vs reduced) also predict survival [208]C4 (4).
Conditioning regimen: High-dose melphalan remains the standard. The propylene glycol-free formulation (PGF-Mel) at 140-200 mg/m² intravenously in two divided doses shows comparable efficacy and safety, with a Day+100 TRM of 0% in a phase II study [231]C4 (4). Dose reduction to 140 mg/m² is common for patients with cardiac or renal compromise, but full-dose melphalan (200 mg/m²) is associated with improved survival, particularly in lambda-restricted disease [228]B2b (2b).
Engraftment and toxicity: Neutrophil engraftment occurs at a median of 10 days and platelet engraftment at 17 days [231]C4 (4). Grade 3-4 mucositis, diarrhea, and fatigue are common. Acute kidney injury occurs in ~50% of patients, with moderate-to-severe AKI in 14%; amyloidosis itself is an independent risk factor for AKI (HR 2.25) [233]B2b (2b). Supportive care with thrombopoietin receptor agonists (e.g., romiplostim N01) may accelerate platelet recovery (median 11 vs 13 days) [238]B2b (2b).
Induction therapy before ASCT: In the modern era, 49-66% of patients receive pre-ASCT induction, most commonly with bortezomib-based regimens [208]C4[235]B2b. This practice deepens response before transplant and may improve outcomes. -based induction, now standard frontline therapy, is often used before ASCT [92]D5 (5).
Allogeneic Stem Cell Transplantation
Allogeneic SCT (allo-SCT) is rarely performed in AL amyloidosis due to high TRM. The EBMT registry reported on 19 patients (15 allo-SCT, 4 syngeneic) between 1991 and 2003: TRM was 40%, and 1-year overall survival was 60% [227]C4 (4). However, achieved complete remissions (CR) were durable, and chronic GVHD correlated with disease control, suggesting a graft-versus-amyloidosis effect. Reduced-intensity conditioning (RIC) was used in 8 of 15 allo-SCT patients. Given the high TRM, allo-SCT is reserved for selected younger patients with relapsed/refractory disease and good performance status, ideally within a clinical trial.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
Anti-BCMA CAR-T therapy is emerging as a promising option for relapsed/refractory AL amyloidosis. The largest reported series (N=16) using the academic HBI0101 CAR-T product (single infusion of 800×10⁶ CAR-T cells after lymphodepletion) showed an overall hematologic response rate of 94% and CR rate of 75% [193]C4 (4). Minimal residual disease negativity was achieved in 9/14 evaluable patients. Organ responses were seen in 8/13 evaluable patients. However, among patients with advanced cardiac disease (MAYO stage IIIa/IIIb), deaths in the first year were frequent, and median overall survival was only 10.1 months (95% CI, 5.8 to not reached) [193]C4 (4).
Toxicity: Cytokine release syndrome (CRS) occurred in 14/16 patients but was mostly low grade (grade 3 in 3, no grade 4/5). No immune effector cell-associated neurotoxicity syndrome (ICANS) or treatment-related deaths were observed [193]C4 (4). These findings extend earlier proof-of-concept data in 4 patients [232]C4 (4).
A BCMA-CD19 dual-targeted CAR-T product (0.3×10⁶/kg) was evaluated in 6 patients with relapsed/refractory disease, all with renal involvement. All 6 achieved hematologic CR and renal response (100% each), with median time to hematologic response of 9 days and renal response of 75 days [239]C4 (4). CRS was grade 1 in 2 patients; no ICANS. One patient developed acute promyelocytic leukemia 15 months post-CAR-T, raising concern for secondary malignancies.
Dosing considerations: CAR-T products are investigational. The target dose for HBI0101 is 800×10⁶ CAR-T cells; for the dual-targeted construct, 0.3×10⁶/kg [193]C4[239]C4 (4). Lymphodepletion with fludarabine (30 mg/m²/day ×3) and (300 mg/m²/day ×3) is used with the dual-targeted product [239]C4 (4).
Bispecific Antibodies and Other BCMA-Directed Therapies
BCMA-directed bispecific antibodies (teclistamab, elranatamab) and antibody-drug conjugates (belantamab mafodotin) are approved for and are under investigation in AL amyloidosis [46]D5 (5). Early data are limited, but these agents may offer off-the-shelf cellular therapy alternatives. The review by Jamroziak et al. notes that despite lower BCMA expression in AL amyloidosis compared to MM, targeting BCMA is promising [46]D5 (5).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Role of ASCT as first-line therapy | NCCN 2024 and ESMO 2024 recommend ASCT as a preferred option for eligible patients with newly diagnosed AL amyloidosis (Category 2A) | The randomized trial by Jaccard et al. [185]A1b (1b) showed no OS benefit; ASCT is not universally accepted as first-line | Strong (RCT vs prospective cohort/guideline recommendations) | ASCT remains a valid option for carefully selected patients, but must be weighed against the efficacy of modern daratumumab-based regimens; decision should be individualized |
| Timing of ASCT, upfront vs after induction? | Mayo Clinic practice, pre-ASCT induction is used in ~50% of patients, especially with bortezomib-based therapy [208]C4 (4) | European practice, some centers advocate for upfront ASCT in low-risk patients without prior therapy [92]D5 (5) | Moderate (no randomized comparison) | Most centers now use induction to deepen response and reduce tumor burden before ASCT |
| CAR-T positioning in the treatment algorithm | ASCO 2023, no formal recommendation for AL amyloidosis; CAR-T is investigational | NCCN 2024, includes BCMA-directed CAR-T as a treatment option for relapsed/refractory AL amyloidosis (Category 2B) | Mild (different guideline bodies, same evidence base) | CAR-T should be considered in the context of clinical trials or for relapsed/refractory disease after exhaustion of established therapies |
Pearl: In carefully selected patients with AL amyloidosis, ASCT achieves a hematologic response rate exceeding 80% with a day-100 mortality of 2-3% in contemporary series; anti-BCMA CAR-T therapy shows remarkable efficacy (94% overall response) but carries a high early mortality in advanced cardiac disease, underscoring the need for earlier intervention and rigorous patient selection [208]C4[193]C4[235]B2b.
| Modality | Typical Dose / Regimen | Hematologic Response Rate | TRM / Early Mortality | Median OS | Key Evidence |
|---|---|---|---|---|---|
| ASCT - Full-dose melphalan | Melphalan 200 mg/m² IV (or PGF-Mel 140-200 mg/m²) | 84% (2010-2016) [208]C4 | 2.4% (Day+100) [208]C4 | Not reached (Mayo 2010-2016) [208]C4; 6.3 years (European 2010-2020) [235]B2b | [208]C4, [235]B2b (2b-4) |
| ASCT - Reduced-dose melphalan | Melphalan 140 mg/m² IV | 69% (1996-2002 cohort) [208]C4 | 14.5% (1996-2002) [208]C4 | 75 months [208]C4 | [208]C4 (4) |
| Allogeneic SCT (RIC) | Varies; fludarabine-based RIC used in 8/15 [227]C4 | CR 53% (8/15 allo-SCT) [227]C4 | 40% (TRM) [227]C4 | 60% at 1 year [227]C4 | [227]C4 (4) |
| Anti-BCMA CAR-T (HBI0101) | 800×10⁶ CAR-T cells IV single infusion | 94% overall, 75% CR [193]C4 | 0% (treatment-related deaths) [193]C4 | 10.1 months (95% CI 5.8-NR) [193]C4 | [193]C4 (4) |
| BCMA-CD19 dual-targeted CAR-T | 0.3×10⁶/kg CAR-T cells IV | 100% CR (6/6) [239]C4 | 0% (treatment-related deaths) [239]C4 | Not reached at median 640 days [239]C4 | [239]C4 (4) |
10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
- ▸Bleeding (9% incidence, 19% mortality) and thrombosis (6% VTE, 5% arterial events) coexist in AL amyloidosis; risk assessment must incorporate liver involvement, creatinine, prior thrombosis, and albumin.
- ▸DOACs are preferred over warfarin for atrial fibrillation in cardiac amyloidosis, reducing thromboembolism by 50% without excess bleeding; anticoagulation is indicated irrespective of CHA2DS2-VASc.
- ▸Cytoreductive therapy carries unique risks: venetoclax for t(11;14) can cause transfusion-dependent cytopenias; melphalan carries an 18% 10-year risk of MDS/AML; diflunisal in ATTR requires monitoring of renal function, hemoglobin, and platelets.
After hematopoietic cell transplantation, the signature hematology triad, blood product support, antithrombotic strategy, and clonal-directed therapy, requires careful tailoring in amyloidosis due to the unique dual risks of bleeding and thrombosis.
Transfusion Support and Bleeding Risk
Bleeding in AL amyloidosis arises from amyloid angiopathy, , and factor X deficiency, compounded by liver involvement [45]D5[138]B2b. Significant bleeding events occur in 9% of patients, with an associated mortality of 19% [138]B2b; liver involvement, higher serum creatinine, and elevated VWF:Ag levels identify those at highest risk [138]B2b.
For transfusion thresholds, a restrictive strategy is safe. In the largest series of autologous stem-cell transplantation (ASCT) without transfusion support (including 2 amyloidosis patients), a platelet transfusion trigger of ≤5 × 10³/μL was appropriate, with no bleeding at counts below that threshold [209]C4 (level 4). Prophylactic aminocaproic acid, phytonadione, erythropoietin, and intravenous iron were used to support hematologic recovery [209]C4.
To accelerate platelet engraftment after ASCT, the thrombopoietin receptor agonist romiplostim N01 (a biosimilar) has been shown to shorten time to platelet engraftment from median 13 days to 11 days and achieve 100% complete platelet recovery by day +30, compared with 66.7% in historical controls [238]B2b (level 2b). This strategy reduces transfusion burden and hospitalization cost [238]B2b.
Anticoagulation and Thrombosis Management
Venous thromboembolic events (VTEs) occur in 6% of AL amyloidosis patients, and arterial embolic events in 5%, with the highest risk clustering in the first year after diagnosis [138]B2b (level 2b). Prior thrombosis is the strongest independent predictor (HR 9.3, p=0.001) [138]B2b; lower serum albumin, lower eGFR, higher bone marrow infiltration, and IMiD-based therapy also increase VTE risk [138]B2b[242]B2b.
For complicating , direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists (VKAs). A meta-analysis of 1,579 patients with cardiac amyloidosis and AF showed DOACs reduce thromboembolic events by 50% (RR 0.50) without a significant increase in major bleeding (RR 0.64) [245]B2a (level 2a). A second meta-analysis confirmed a reduced odds of thromboembolism (OR 0.52) and no difference in major bleeding [246]B2a (level 2a). Anticoagulation is indicated irrespective of CHA₂DS₂-VASc score in cardiac amyloidosis [250]D5.
Left atrial appendage occlusion (LAAC) is a safe alternative in patients with high bleeding risk: a retrospective study of 21 patients (90.5% wild-type ATTR) reported 95% procedural success, no device-related thrombosis, and 9.5% major bleeding (all while on post-procedural OAC) [83]B3b (level 3b). However, 2 patients (9.5%) had ischemic stroke despite DOAC, highlighting residual risk [83]B3b.
Elective cardioversion of AF requires OAC for ≥3 weeks before and ≥4 weeks after, regardless of CHA₂DS₂-VASc, because cardiac amyloidosis itself is a risk factor for post-cardioversion thromboembolism [251]D5 (level 5).
Cytoreductive and Clonal-Directed Therapy
For AL amyloidosis with t(11;14), venetoclax-based regimens achieve 78% overall response rate in heavily pretreated relapsed/refractory , and one patient with cardiac amyloidosis attained a cardiac organ response [240]C4 (level 4). Hematologic toxicities requiring transfusion support are common [240]C4.
Long-term surveillance for myelodysplasia (MDS)/acute myeloid leukemia is mandatory after melphalan-based therapy: the actuarial risk of MDS/AML at 10 years is 18% [243]B2b (level 2b).
In ATTR amyloidosis, the nonsteroidal anti-inflammatory drug diflunisal reduces mortality by 77% but causes declines in eGFR, hemoglobin, and platelet count; 24% of patients discontinue therapy, most commonly for renal impairment (21%) [247]B2a (level 2a). Switching from the TTR silencer inotersen to eplontersen restores platelet count toward baseline (mean nadir reduction -3.2% vs -40.7%) and improves tolerability [241]B2b (level 2b).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| DOAC vs VKA for AF in cardiac amyloidosis | Meta-analyses [245]B2a[246]B2a support DOAC superiority (reduced thromboembolism, similar bleeding) | Some guidelines may still prefer VKA in patients with severe renal impairment or valvular AF | Mild (evidence consistent but not yet guideline-universal) | Clinicians should use DOACs as first-line in cardiac amyloidosis-AF, adjusting for renal function |
| Role of LAAC vs continued OAC | LAAC feasible and safe (single-center, small series) [83]B3b | No randomized comparison; OAC remains standard in most guidelines [250]D5 | Moderate (LAAC data limited) | LAAC is an option for patients with contraindications to OAC or high bleeding risk; shared decision-making advised |
Pearl: In AL amyloidosis, balance bleeding and thrombotic risks by using restrictive transfusion thresholds (platelet ≤5 × 10³/μL) and DOACs for atrial fibrillation; monitor for MDS after melphalan and for renal impairment and cytopenias with diflunisal in ATTR.
| Option | Evidence | Thromboembolic reduction | Major bleeding | Special considerations |
|---|---|---|---|---|
| VKA (warfarin) | Historical standard | Reference | Reference | Labile INR due to amyloid liver involvement; drug-drug interactions |
| Left atrial appendage occlusion | Observational study [83]B3b (3b) | Residual stroke 9.5% despite DOAC | Major bleeding 9.5% (on OAC) | High procedural success (95%); consider in high bleeding risk or contraindication to OAC |
| Strategy | Setting | Threshold/Dose | Evidence |
|---|---|---|---|
| Platelet transfusion trigger | ASCT without transfusion support | ≤5 × 10³/μL [209]C4 | Level 4 (case series, n=2 amyloidosis) |
| Romiplostim N01 (thrombopoietin agonist) | Post-ASCT | 250 μg SC weekly until platelet count >50 × 10³/μL [238]B2b | Level 2b (retrospective cohort; median engraftment 11 days) |
| Aminocaproic acid | Post-ASCT prophylaxis | 1 g IV every 6 hours [209]C4 | Level 4 |
| Phytonadione (vitamin K) | Post-ASCT prophylaxis | 5 mg IV daily [209]C4 | Level 4 |
History and Evolution of Treatment
- ▸Daratumumab-CyBorD is the current standard of care for newly diagnosed AL amyloidosis, based on the ANDROMEDA trial showing a 53% complete response rate and 42% reduction in organ deterioration.
- ▸High-dose melphalan with ASCT was not superior to standard-dose melphalan-dexamethasone in a randomized trial, limiting its use to carefully selected patients after induction therapy.
- ▸RNA interference agents (patisiran, vutrisiran) and antisense oligonucleotides (inotersen, eplontersen) have transformed the management of ATTR amyloidosis, reducing mortality and preserving function.
Building on the foundations of supportive care and cytoreduction, the treatment of amyloidosis has been reshaped by a series of landmark trials, each phase refining the target and the approach.
The Era of Alkylating Agents (1970s-1990s)
The first randomized trial in AL amyloidosis compared melphalan plus to placebo [255]A1b. Although survival did not differ significantly, the regimen produced objective responses, including resolution of nephrotic syndrome in two patients and >50% reduction in proteinuria in eight others [255]A1b. Colchicine, tested against melphalan-prednisone in a three-arm trial, proved inferior: median survival was 8.5 months with colchicine vs 18 months with melphalan-prednisone (P<0.001) [256]A1b. Multi-agent chemotherapy (VBMCP) offered no advantage over melphalan-prednisone [257]A1b. For two decades, oral melphalan-prednisone remained the default.
The High-Dose Melphalan Controversy
High-dose melphalan with autologous stem cell transplantation (ASCT) became widely used based on single-arm data. The randomized trial by Jaccard et al. [185]A1b shattered that assumption: median overall survival was 22.2 months with ASCT vs 56.9 months with standard-dose melphalan plus (P=0.04). Among low-risk patients, the trend favored non-transplant therapy (80% vs 58% at 3 years, P=0.13). ASCT was not abandoned but became reserved for carefully selected patients after induction therapy, as shown in the HOVON 104 trial where 30% of patients could not proceed to transplant after bortezomib-based induction [195]C4.
The Bortezomib Revolution
Bortezomib-based regimens changed the landscape. The combination of bortezomib, melphalan, and dexamethasone (BMDex) improved hematologic response rate at 3 months to 79% vs 52% with MDex alone, and halved mortality (HR 0.50, 95% CI 0.27-0.90) [186]A1b. , bortezomib, and dexamethasone (CyBorD) became the backbone of frontline therapy, achieving rapid responses even in high-risk stage III patients [280]C4. A matched comparison showed CyBorD produced higher complete response rates (40.5% vs 24.6%) and improved progression-free survival compared to thalidomide-based regimens [286]B2b.
The Era
The ANDROMEDA trial [15]A1b randomized 388 newly diagnosed patients to daratumumab-CyBorD vs CyBorD alone. The hematologic complete response rate was 53.3% vs 18.1% (RR 2.9, 95% CI 2.1-4.1; P<0.001; NNT = 3 to achieve one additional complete response). Major organ deterioration or hematologic progression was reduced by 42% (HR 0.58, 95% CI 0.36-0.93). Cardiac and renal responses at 6 months were nearly doubled (41.5% vs 22.2% and 53.0% vs 23.9%, respectively). Daratumumab-CyBorD is now the standard of care for newly diagnosed AL amyloidosis. Notably, stage IIIb patients, excluded from ANDROMEDA, also benefit: upfront daratumumab-based therapy improved median overall survival from 6.6 months to not reached in a retrospective series [214]B2b.
Anti-Fibril Antibodies: Targeting the Amyloid Itself
The anti-amyloid antibody birtamimab showed no benefit in the overall VITAL trial [183]A1b, but a post hoc analysis in Mayo stage IV patients suggested a survival advantage (74% vs 49% at 9 months; HR 0.413). The confirmatory AFFIRM-AL trial is ongoing. Anselamimab [187]A1b failed its primary endpoint in the overall population but demonstrated a 62% reduction in all-cause mortality in the kappa isotype subgroup (HR 0.38, 95% CI 0.17-0.86). These agents may become important adjuncts for specific subsets.
Treatment of ATTR Amyloidosis
For hereditary transthyretin amyloidosis with polyneuropathy, patisiran [67]A1b and inotersen [16]A1b both demonstrated improvements in neuropathy impairment scores. Patisiran reduced the mNIS+7 by 34.0 points vs placebo (P<0.001) [67]A1b. Inotersen showed a similar benefit (difference in mNIS+7: -19.7 points, 95% CI -26.4 to -13.0) but required enhanced monitoring for thrombocytopenia and glomerulonephritis [16]A1b. Vutrisiran [66]A1b and eplontersen [278]B2b[279]B2b offer subcutaneous dosing with comparable efficacy. For ATTR cardiomyopathy, vutrisiran reduced all-cause mortality and cardiovascular events (HR 0.72, 95% CI 0.56-0.93; NNT = 10 to prevent one primary endpoint event over 36 months) and preserved functional capacity [66]A1b. Patisiran showed similar benefit in functional capacity [184]A1b. Gene editing approaches are on the horizon [263]A1c.
Treatment of AA Amyloidosis
Eprodisate, a glycosaminoglycan-interfering agent, slowed the decline of renal function in a randomized trial (HR 0.58, 95% CI 0.37-0.93) [68]A1b but did not improve survival. The cornerstone of AA amyloidosis remains suppression of the underlying inflammatory disease to reduce serum amyloid A production [97]B2b.
Pearl: The treatment of AL amyloidosis has evolved from empirical alkylator therapy to daratumumab-based chemoimmunotherapy, achieving complete response rates exceeding 50% in newly diagnosed patients; in ATTR, RNA interference and antisense therapies now offer disease-modifying options for both polyneuropathy and cardiomyopathy, with gene editing on the horizon.
| Trial | Year | Population | Regimen | Key Result | Reference |
|---|---|---|---|---|---|
| Melphalan-prednisone vs placebo | 1978 | AL | Melphalan + prednisone | Objective responses but no survival benefit | [255]A1b |
| Colchicine vs melphalan-prednisone | 1997 | AL | Melphalan + prednisone | Median OS 18 vs 8.5 months (P<0.001) | [256]A1b |
| High-dose melphalan vs MDex | 2007 | AL | ASCT vs melphalan-dexamethasone | Median OS 22.2 vs 56.9 months (P=0.04) favoring MDex | [185]A1b |
| BMDex vs MDex | 2020 | AL | Bortezomib + melphalan + dexamethasone | HR 0.50 for OS; 79% vs 52% hematologic response | [186]A1b |
| ANDROMEDA | 2021 | AL | Daratumumab-CyBorD vs CyBorD | 53% vs 18% CR; HR 0.58 for organ deterioration | [15]A1b |
| APOLLO | 2018 | ATTRv-PN | Patisiran vs placebo | mNIS+7 difference -34.0 points (P<0.001) | [67]A1b |
| NEURO-TTR | 2018 | ATTRv-PN | Inotersen vs placebo | mNIS+7 difference -19.7 points (P<0.001) | [16]A1b |
| HELIOS-B | 2024 | ATTR-CM | Vutrisiran vs placebo | HR 0.72 for mortality/CV events; NNT 10 | [66]A1b |
| VITAL | 2023 | AL (stage IV) | Birtamimab + SOC | Post hoc 74% vs 49% survival at 9 months | [183]A1b |
| CARES | 2026 | AL (stage III) | Anselamimab + SOC | Kappa subgroup: HR 0.38 for mortality | [187]A1b |
11. Complications
- ▸Cardiac involvement dominates prognosis in AL amyloidosis, with atrial fibrillation in 18% and arrhythmias in 26% of treated patients [291][198].
- ▸Hematologic toxicity (neutropenia 45%, thrombocytopenia 27% with lenalidomide) is the most common treatment-related adverse event [260].
- ▸The 2-year dialysis rate in relapsed AL amyloidosis is 15%, underscoring the need for renal monitoring [295].
Building on the evolution of treatment, clinicians must now contend with complications arising from both the amyloidogenic process and its therapies. These span multiple organ systems and require vigilant monitoring and preemptive .
Disease-Related Complications
Cardiac involvement dominates prognosis. is reported in 18% of -treated patients and cardiac arrhythmias in 26% of those receiving ixazomib [291]C4[198]A1b. Heart failure can progress rapidly; in patients with and concomitant cardiac AL amyloidosis, all-cause mortality at 12 months is nearly five times higher than in those without cardiac involvement (RR 4.25; 95% CI 1.99-9.04; RMST 27.28 months shorter) [298]A1a. Renal dysfunction is the leading manifestation of AA amyloidosis, and the 2-year dialysis rate in relapsed AL reaches 15% [97]B2b[295]B2b. Autonomic involvement manifests as orthostatic hypotension, constipation, and urinary retention, often exacerbated by proteasome inhibitor therapy [199]C4[157]B2b. , both disease- and treatment-related, frequently complicates bortezomib-based regimens, necessitating dose adjustments in a majority of patients [199]C4[157]B2b.
Treatment-Related Complications
Hematologic toxicity is the most common therapy-related adverse event. Lenalidomide causes grade 3/4 neutropenia in 45% and thrombocytopenia in 27% of patients [260]C4; -containing regimens produce grade ≥3 hematologic toxicity in 46% [90]C4. Infection risk is substantial: grade ≥3 respiratory infections occur in 18% with daratumumab, and the mortality rate in patients with hematologic malignancies including amyloidosis is 28% [291]C4[74]C4. Fluid retention and peripheral edema are frequent with immunomodulatory drugs and bortezomib [199]C4[292]C4. Rash complicates lenalidomide therapy in 18% of patients (grade 3/4 in 16% with VRD) [260]C4[211]C4. Infusion reactions are rare with daratumumab (none grade 3-4), but cytokine release syndrome occurs in the majority of patients receiving anti-BCMA CAR-T cells, though mostly low-grade [291]C4[193]C4. Treatment-related mortality is reported at 4% with CTD and up to 20% on-study death in advanced disease with CRd [17]C4[90]C4.
Supportive Care and Monitoring
Respiratory monitoring: Frequent assessment of volume status and oxygen saturation is essential, as pulmonary congestion from cardiac involvement and infections are common. Autonomic complications: Orthostatic blood pressure measurements should guide volume repletion and dose adjustments of vasoactive medications. DVT/PE prophylaxis: Anticoagulation is indicated for atrial fibrillation, but bleeding risk must be weighed; left atrial appendage occlusion is a safe alternative (procedural success 95% , no device thrombosis) [83]B3b. Pain management: Neuropathic pain from bortezomib responds to dose reduction and adjuvants such as gabapentin. Rehabilitation: Early physical therapy can mitigate deconditioning from prolonged hospitalization. Hospital-acquired complications: Strict infection control, skin care to prevent pressure injuries, and bladder management reduce secondary morbidity.
Complication Overview
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Atrial fibrillation / arrhythmias | 18-26% [291]C4[198]A1b | Baseline ECG, electrolyte optimization | Rate/rhythm control, anticoagulation balancing bleeding risk |
| Grade ≥3 infection (respiratory) | 6-18% [188]C4[291]C4 | Vaccination, infection control, immunoglobulin if hypogammaglobulinemia | Empiric , dose delay of therapy |
| Neutropenia (grade 3/4) | 45% [260]C4 | Growth factor support (G-CSF) per guidelines | Dose reduction or hold |
| Peripheral neuropathy | Up to 20% grade 2 [211]C4 | Cautious dose escalation of bortezomib; monitor vibration sense | Dose reduction, switch to carfilzomib or ixazomib |
| Fluid retention / edema | Common [199]C4[292]C4 | Baseline diuretic if nephrotic; daily weights | Loop diuretics, dose reduction of lenalidomide |
| Cytokine release syndrome (CAR-T) | 88% (14/16) [193]C4 | Premedication, close monitoring | , corticosteroids if grade ≥2 |
| Renal progression (end-stage) | 15% at 2 years [295]B2b | SAA suppression in AA; deep hematologic response in AL | Dialysis; consider eprodisate in AA [68]A1b |
Pearl: The single most modifiable predictor of organ deterioration in AA amyloidosis is the serum amyloid A concentration, patients whose SAA remains < 4 mg/L have a risk of death nearly 18-fold lower than those with SAA > 155 mg/L [97]B2b.
12. Prognosis & Natural History
- ▸Mayo 2012 staging remains the backbone of risk stratification, but baseline dFLC >180 mg/L may no longer carry independent prognostic weight in the era of daratumumab-based regimens.
- ▸Achieving a hematologic complete response and a cardiac response (NT-proBNP reduction ≥60%) are the strongest modifiable predictors of long-term survival.
- ▸Bone marrow plasma cell burden ≥20% and high-risk cytogenetics define a myeloma-like phenotype with poor prognosis independent of cardiac stage.
The natural history of untreated AL amyloidosis is relentlessly progressive, with a historical median survival of 12-18 months from diagnosis. Contemporary outcomes have improved dramatically with effective anti-clonal therapy, but prognosis remains heterogeneous and tightly linked to the depth of hematologic response and the extent of cardiac involvement at presentation.
Survival by Risk Stage
The Mayo 2012 staging system (Section 6) remains the most widely validated prognostic framework. In the original derivation cohort of 810 patients, median overall survival (OS) was:
| Stage | Score | Median OS (months) |
|---|---|---|
| I | 0 | 94.1 |
| II | 1 | 40.3 |
| III | 2 | 14.0 |
| IV | 3 | 5.8 |
Source: Kumar et al. [4]B2b
The European modification (revised Mayo 2004) further subdivides stage III into IIIa (NT‑proBNP <8500 ng/L) and IIIb (≥8500 ng/L) [131]B2b. Stage IIIb carries a particularly grim prognosis: in a contemporary series of 142 patients, the median OS was 9 months [131]B2b. Among patients with advanced cardiac disease, a 6‑minute walk distance <200 m and III/IV independently predict shorter survival [131]B2b.
Prognostic Factors Beyond Stage
Hematologic response depth is the strongest modifiable determinant of survival. In the ANDROMEDA trial, the addition of to bortezomib- - (D‑VCd) yielded a hematologic complete response rate of 59.5% and a 38% reduction in mortality (HR 0.62, 95% CI 0.42-0.90) over a median follow‑up of 61.4 months [300]A1b. Achieving a cardiac response (NT‑proBNP reduction ≥60%) is independently associated with longer survival: 5‑year OS rates of 93% for cardiac complete response versus 33% for no cardiac response [124]B3b.
Bone marrow plasma cell burden (BMPC) ≥20% identifies a myeloma‑like phenotype with worse outcome independent of cardiac stage, median OS 12 months versus 81 months for BMPC <5% [141]B2b. High‑risk cytogenetic abnormalities (del17p, t(4;14), t(14;16), t(14;20)) are associated with deeper cardiac responses but not with overall survival after adjustment for treatment [39]B2b.
Outcomes in Other Amyloidosis Types
Localized AL amyloidosis has an excellent prognosis: 5‑year OS and 10‑year OS, with progression to systemic disease in only 1% of patients [205]C4. For AA amyloidosis, median survival is 133 months, and the risk of death is 17.7‑fold higher when serum amyloid A (SAA) remains ≥155 mg/L versus <4 mg/L [97]B2b. In ATTR cardiomyopathy, tafamidis reduces all‑cause mortality in octogenarians by 49% (HR 0.51, 95% CI 0.40-0.67) [221]A1a, and the RNA‑silencing agent vutrisiran has shown a 28-35% reduction in mortality (HR 0.65-0.72) in the HELIOS‑B trial [222]D5.
The Impact of Treatment Era
Contemporary outcomes have improved substantially. The 5‑year OS in the daratumumab era of the ANDROMEDA trial reached 76% [121]D5[300]A1b. However, patients with relapsed/refractory disease still face a poor outlook: median OS 18.2 months with bendamustine-dexamethasone [293]C4 and 10.1 months with anti‑BCMA CAR‑T therapy in a heavily pretreated cohort [193]C4. The prognosis in elderly patients and those with advanced cardiac disease merits special consideration, as discussed in the following section on special populations.
Pearl: Bone marrow plasma cell burden ≥20% and high-risk cytogenetics define a myeloma-like phenotype with poor prognosis independent of cardiac stage.
| Stage | Score | Median OS (months) |
|---|---|---|
| I | 0 | 94.1 |
| II | 1 | 40.3 |
| III | 2 | 14.0 |
| IV | 3 | 5.8 |
13. Special Populations & Pregnancy
- ▸Pediatric amyloidosis is largely secondary to autoinflammatory syndromes (FMF); anti-IL-1 therapy can prevent AA amyloidosis.
- ▸In elderly patients, tafamidis reduces all-cause mortality in ATTR-CM by 49% (HR 0.51) [221]; AL therapy should target ≥VGPR.
- ▸High-dose melphalan with ASCT is feasible in severe renal impairment, with 24% becoming dialysis-independent [244].
Prognosis in amyloidosis is heavily influenced by organ involvement and depth of hematologic response, but these outcomes are not uniform across all patients; host factors such as age, pregnancy, renal function, and pediatric status mandate specific modifications in diagnostic workup and therapeutic strategy.
Pediatrics
Amyloidosis in children is rare and almost always secondary to an underlying autoinflammatory condition, most commonly (FMF) [107]D5. In pediatric FMF cohorts, homozygous exon 10 variants (especially M694V) predict severe disease with higher attack frequency, colchicine resistance, and risk of AA amyloidosis [305]B3b. Anti-IL-1 agents (e.g., , ) are increasingly used for refractory disease, reducing the risk of amyloid deposition [305]B3b. In children with AL amyloidosis, extremely rare, high-dose melphalan and autologous stem cell transplantation are avoided due to unacceptable toxicity; instead, bortezomib-based regimens are dose-adjusted for weight and renal function, with close monitoring for neuropathy. Prognosis is driven by the underlying disease: early treatment of FMF has made AA amyloidosis an uncommon complication.
Pregnancy
AL amyloidosis during pregnancy is exceptionally rare; requires a multidisciplinary team (hematology, cardiology, obstetrics). Many chemotherapeutic agents, , , , are teratogenic and contraindicated in the first trimester [label]. If treatment is necessary during the second or third trimester, cautious use of corticosteroids or (with strict contraception) may be considered, but data are limited. Cardiac involvement, particularly restrictive cardiomyopathy, increases the risk of heart failure during pregnancy and may necessitate cesarean delivery. is contraindicated during active chemotherapy. Preconception counseling and ovarian preservation with should be discussed for patients of childbearing potential.
Elderly
Amyloidosis is increasingly diagnosed in patients aged ≥75 years, who represent a growing proportion of the population [20]B2b. Comorbidities, frailty, and polypharmacy compound the challenges. In AL amyloidosis, deep hematologic responses (≥VGPR) are associated with excellent survival even in the elderly, but non-responders have outcomes similar to untreated patients (median OS 1.5 years vs. 8.4 months with supportive care alone) [20]B2b. High-dose melphalan with ASCT is generally not recommended; instead, dose-reduced bortezomib-based regimens or - are first-line, with careful attention to cardiac function and renal reserve. In ATTR cardiomyopathy, is well-tolerated and effective in octogenarians (mean age 84 years), reducing all-cause mortality by 49% (HR 0.51, 95%; NNT not calculable from reported data) [221]A1a. Geriatric assessment (e.g., performance status, fall risk, cognitive function) should guide treatment intensity.
Immunocompromised (Renal/Hepatic Impairment)
Renal impairment is frequent in both AL and ATTR amyloidosis. High-dose melphalan (median 140 mg/m²) with ASCT is feasible in patients with creatinine clearance <20 mL/min or on dialysis, with reported day-100 transplant-related mortality of and 24% becoming dialysis-independent [244]C4. , a TTR stabilizer, slows eGFR decline in ATTR-CM with renal impairment (≥40% eGFR decline in 12.7% vs. 21.2% with placebo) and is effective in those developing CKD stage ≥4 (HR 0.467) [276]B2b. Hepatic impairment requires dose adjustments for and due to reduced clearance; no dose change is needed for in mild-moderate hepatic impairment. For patients on dialysis, melphalan dose should be reduced by 25-50% and given after dialysis to avoid prolonged myelosuppression.
Pearl: In elderly patients with AL amyloidosis, achieving at least a VGPR with first-line therapy is the strongest predictor of survival, non-responders should be considered for alternative regimens early, as their outcomes mirror those of untreated patients [20]B2b.
| Population | Therapy | Modification | Key Evidence |
|---|---|---|---|
| Pediatrics (FMF) | Colchicine, anti-IL-1 | Dose by weight; avoid ASCT | [305]B3b |
| Pregnancy | Bortezomib, lenalidomide | Avoid first trimester; multidisciplinary delivery planning | [label] |
| Elderly (ATTR-CM) | Tafamidis | No dose adjustment needed; assess frailty | [221]A1a |
| Elderly (AL) | Bortezomib-dexamethasone | Dose-reduced; avoid HDT-ASCT | [20]B2b |
| Renal impairment (AL) | Melphalan (HDT) | Reduce to 140 mg/m²; give after dialysis | [244]C4 |
| Renal impairment (ATTR) | Vutrisiran | No dose adjustment; slows eGFR decline | [276]B2b |
14. Prevention, Screening & Surveillance
- ▸MASS-FIX testing for glycosylated light chains identifies MGUS patients with a 20-year progression risk to AL amyloidosis of 21%, compared to 3% in those without glycosylation [82].
- ▸Serial FLC measurements are the preferred surveillance tool in AL amyloidosis, outperforming serum PEL and immunofixation [18].
- ▸Any patient with apparent AL amyloidosis and atypical features should undergo genetic testing for hereditary variants, as 2% of symptomatic patients have both conditions [309].
For patients with known monoclonal gammopathy of undetermined significance (MGUS), the transition from screening to surveillance begins with the recognition that not all clones are equal. The combination of serum protein electrophoresis (PEL), immunofixation, and the serum free light chain (FLC) assay in the initial evaluation yields high sensitivity for detecting a plasma cell disorder, and in most cases negates the need for 24-hour urine studies except when light chain (AL) amyloidosis is suspected [18]A1c. Screening for early organ damage using biomarkers can identify patients with MGUS who are developing AL amyloidosis before they become symptomatic [26]D5.
Primary Prevention: Identifying the At-Risk Clone
No pharmacologic intervention has been shown to prevent the development of AL amyloidosis in patients with MGUS. However, the identification of monoclonal light chain (LC) glycosylation by routine MASS-FIX testing is a potent risk factor for progression to AL, myeloma, and other plasma cell disorders. In a cohort from the Olmsted MGUS screening study, patients with glycosylated LCs had a 20-year progression rate to a malignant plasma cell disorder of 67% (95% CI 29%, 84%) compared with 13% (95% CI 9%, 18%) for those without; the respective rates of progression to AL at 20 years were 21% (95% CI 0.0%, 38%) and 3% (95% CI 0.6%, 5.5%) [82]B2b. This risk was independent of the Mayo MGUS risk score, suggesting that MASS-FIX testing could refine surveillance intervals [82]B2b.
Secondary Prevention: Surveillance After Diagnosis and Treatment
In AL amyloidosis, serial FLC measurements outperform PEL and immunofixation for monitoring [18]A1c. The goal is to normalize the involved free light chain, which leads to improvement or at least stabilization of organ function in most responding patients [294]C4. For patients who achieve at least a hematologic partial response, graded cardiac response criteria using N-terminal prohormone of brain natriuretic peptide (NT-proBNP) provide better prognostic stratification than binary response. Best cardiac complete response (CarCR) is achieved in 16% of patients, with 5-year overall survival of 93% for CarCR vs 33% for cardiac no response (CarNR) [124]B3b. Surveillance echocardiography and ECG should be performed at 6-month intervals, with AI-assisted interpretation showing promise for distinguishing from other causes of (AUC 0.96 in external validation) [142]B2b.
Hereditary Amyloidosis: Cascade Testing and Gene Editing
Hereditary amyloidosis can be misdiagnosed as AL because family history is an ineffective screen and tissue staining is unreliable. In one series, 6% of patients screened for hereditary variants and 2% of all symptomatic patients had both a monoclonal gammopathy and a hereditary variant [309]C4. Therefore, any patient with apparent AL who has atypical features, no clonal dominance, or a family history of neuropathy or cardiomyopathy should undergo genetic testing for transthyretin (TTR), apolipoprotein AI, apolipoprotein AII, fibrinogen Aalpha, and lysozyme variants [309]C4. When a pathogenic variant is identified, cascade testing of first-degree relatives is recommended. For ATTR amyloidosis, gene editing therapies using CRISPR-Cas9 delivered via lipid nanoparticles are on the horizon as curative single-treatment strategies, with the liver as the key target organ [263]A1c. Meanwhile, vutrisiran, a subcutaneously administered small interfering RNA therapy, suppresses hepatic transthyretin synthesis and has shown a reduction in all-cause mortality (HR 0.65-0.72) and cardiovascular events (HR 0.67-0.72) in ATTR cardiomyopathy [222]D5.
Vaccine Considerations
Patients with AL amyloidosis should receive all standard vaccines, including influenza, pneumococcal, and vaccines, because of their immunosuppressed state from plasma cell dyscrasia and chemotherapy. Live attenuated vaccines are contraindicated during active treatment. There is no evidence that vaccination triggers amyloid deposition or disease progression.
Patient Education
Patients should be counseled about the importance of regular follow-up, the significance of new symptoms (especially dyspnea, edema, and neuropathy), and the need for adherence to cardiac and renal surveillance. Education about the risk of progression (for MGUS patients with glycosylated LCs, 21% at 20 years) helps set realistic expectations [82]B2b.
Pearl: In any patient with MGUS, MASS-FIX testing for glycosylated light chains provides a 7-fold higher 20-year risk of progression to AL (21% vs 3%) and should be considered to tailor surveillance intervals [82]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should all patients with MGUS undergo MASS-FIX testing? | IMWG: FLC assay and PEL/immunofixation sufficient for screening [18]A1c | Emerging data: glycosylated LC by MASS-FIX identifies high-risk MGUS independent of Mayo risk score [82]B2b | Moderate | If MASS-FIX is available, it may refine risk stratification; cost-effectiveness remains unproven |
| What is the role of gene editing in ATTR amyloidosis? | ACC 2026 statement: CRISPR-Cas9 approaches are imminent for monogenic liver-based diseases [263]A1c | No current regulatory approval; long-term safety data lacking | Low | Patients should be counseled about clinical trial availability, not routine use |
| Population | Modality | Frequency | Target |
|---|---|---|---|
| MGUS (low risk) | SPEP, immunofixation, FLC | Every 12 months [18]A1c | Detect progression to AL or MM |
| MGUS (glycosylated LC) | MASS-FIX, FLC | Every 6 months [82]B2b | Early detection of AL or MM |
| AL amyloidosis (post-treatment) | FLC, NT-proBNP, troponin, echocardiography, ECG | Every 6 months [124]B3b | Assess cardiac and hematologic response; detect relapse |
| Hereditary ATTR carriers | TTR genotyping, echocardiography, cardiac biomarkers | Every 12 months (or at symptom onset) [263]A1c | Monitor for disease onset |
| ATTR cardiomyopathy (on vutrisiran) | NT-proBNP, troponin I, echocardiography, 6MWT, KCCQ-OS | Every 6 months [222]D5 | Assess response to therapy |
References
- [1]
Schönland SO, Hegenbart U, Bochtler T et al.. “Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.” Blood (2011). PMID: 22106346 ↗
L4OTHERCited in: 1. Definition, Classification & Nomenclature, 4. Clinical Presentation - [2]
Vrana JA, Gamez JD, Madden BJ et al.. “Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.” Blood (2009). PMID: 19797517 ↗
L3OTHERCited in: 1. Definition, Classification & Nomenclature, 3. Epidemiology, Etiology & Risk Factors - [3]
Brambilla F, Lavatelli F, Di Silvestre D et al.. “Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.” Blood (2011). PMID: 21917755 ↗
L3OTHERCited in: 1. Definition, Classification & Nomenclature - [4]
Kumar S, Dispenzieri A, Lacy MQ et al.. “Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22331953 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature, 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [5]
Burgos L, Tamariz-Amador LE, Puig N et al.. “Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36930848 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature, 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring - [6]
Guinault D, Canet E, Huart A et al.. “Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.” British journal of haematology (2016). PMID: 27292694 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature - [7]
Mir TH, Santos-Patarroyo SD, Freed JA et al.. “Monoclonal gammopathies of thrombotic and hemorrhagic significance: mapping into a classification schema.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41850491 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification & Nomenclature, 8. Long-term & Definitive Management - [8]
Puig N, Paiva B, Lasa M et al.. “Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.” Leukemia (2018). PMID: 30542145 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature, 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 14. Prevention, Screening & Surveillance - [9]
Coleman CI, Martinez R, Torres SA. “Methods of identifying transthyretin amyloid cardiomyopathy in secondary data sources: a systematic review.” Current medical research and opinion (2025). PMID: 41359351 ↗
L2SR_OBSCited in: 1. Definition, Classification & Nomenclature - [10]
Ferrin PC, Daly G, Lipira AB et al.. “Amyloidosis Screening by Biopsy During Carpal Tunnel Release: A Systematic Review and Meta-analysis.” Plastic and reconstructive surgery. Global open (2025). PMID: 40438527 ↗
L2SR_OBSCited in: 1. Definition, Classification & Nomenclature - [11]
Ma Y, Li T, Li X. “Waldenström macroglobulinemia complicated with AL λ - type amyloid nephropathy: a case report and literature review.” Frontiers in medicine (2026). PMID: 42063792 ↗
L4CASE_REPORTCited in: 1. Definition, Classification & Nomenclature, 2. Pathophysiology & Mechanism, 4. Clinical Presentation, 6. Staging, Risk Stratification & Prognostic Scoring - [12]
Monaco I, Sedrati M, Chouarfia I et al.. “Small Hearts, Big Clues: A Narrative Review on Sex-Related Disparities in the Diagnosis and Management of Cardiac Amyloidosis in Women.” Journal of clinical medicine (2026). PMID: 42355987 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification & Nomenclature - [13]
Nakamura M, Imamura T, Nakagaito M et al.. “Better Outcomes After Initiation of Disease-Modifying Therapy in Patients with Transthyretin Cardiac Amyloidosis.” Journal of clinical medicine (2026). PMID: 42355714 ↗
L4OTHERCited in: 1. Definition, Classification & Nomenclature - [14]
Arık SD, Kayaalp GK, Kılınç AD et al.. “Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.” Paediatric drugs (2026). PMID: 42270889 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature - [15]
Kastritis E, Palladini G, Minnema MC et al.. “Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.” The New England journal of medicine (2021). PMID: 34192431 ↗
L1RCTCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [16]
Benson MD, Waddington-Cruz M, Berk JL et al.. “Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.” The New England journal of medicine (2018). PMID: 29972757 ↗
L1RCTCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, History and Evolution of Treatment - [17]
Wechalekar AD, Goodman HJ, Lachmann HJ et al.. “Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.” Blood (2006). PMID: 16990593 ↗
L4TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 11. Complications - [18]
Dispenzieri A, Kyle R, Merlini G et al.. “International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.” Leukemia (2008). PMID: 19020545 ↗
L1GUIDELINECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance - [19]
Staron A, Burks EJ, Lee JC et al.. “Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.” Blood advances (2020). PMID: 32130406 ↗
L4TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [20]
Sachchithanantham S, Offer M, Venner C et al.. “Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.” Haematologica (2015). PMID: 26294730 ↗
L2TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy - [21]
Sharpley FA, Manwani R, Mahmood S et al.. “Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.” British journal of haematology (2018). PMID: 30095161 ↗
L4TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 11. Complications - [22]
Treon SP. “How I treat Waldenström macroglobulinemia.” Blood (2015). PMID: 26002963 ↗
L5CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 12. Prognosis & Natural History - [23]
Palladini G, Merlini G. “How I treat AL amyloidosis.” Blood (2022). PMID: 34517412 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [24]
Gort-Freitas NA, Moscvin M, Da Vià MC et al.. “Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment.” Blood (2025). PMID: 40493887 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [25]
Benson MD, Liepnieks JJ, Kluve-Beckerman B. “Hereditary systemic immunoglobulin light-chain amyloidosis.” Blood (2015). PMID: 25858898 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [26]
Palladini G, Merlini G. “What is new in diagnosis and management of light chain amyloidosis?” Blood (2016). PMID: 27053535 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 14. Prevention, Screening & Surveillance - [27]
Paiva B, Martinez-Lopez J, Corchete LA et al.. “Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.” Blood (2016). PMID: 27069257 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [28]
Adams D, Algalarrondo V, Echaniz-Laguna A. “Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments.” Blood (2023). PMID: 37624911 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [29]
Merlini G, Seldin DC, Gertz MA. “Amyloidosis: pathogenesis and new therapeutic options.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21483018 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management - [30]
Kourelis TV, Kumar SK, Gertz MA et al.. “Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145344 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring - [31]
Oschlies I, Richter J, Alfert A et al.. “Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection.” Blood advances (2025). PMID: 40493885 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 11. Complications - [32]
Lopedote P, Evans B, Marchetti A et al.. “Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis.” Blood advances (2024). PMID: 38652890 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 12. Prognosis & Natural History - [33]
Saunders CN, Chattopadhyay S, Huhn S et al.. “Search for AL amyloidosis risk factors using Mendelian randomization.” Blood advances (2021). PMID: 34228109 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors - [34]
Rius B, Mesgarzadeh JS, Romine IC et al.. “Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion.” Blood advances (2021). PMID: 33599742 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism, 11. Complications - [35]
Bochtler T, Merz M, Hielscher T et al.. “Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.” Blood advances (2018). PMID: 30327369 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment - [36]
Bianchi G, Sanchorawala V, Wechalekar A et al.. “Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions.” Lancet (London, England) (2026). PMID: 42419329 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [37]
Khwaja J, D'Sa S, Minnema MC et al.. “IgM monoclonal gammopathies of clinical significance: diagnosis and management.” Haematologica (2022). PMID: 35770530 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [38]
Pick M, Lebel E, Elgavish S et al.. “Amyloidogenic light chains impair plasma cell survival.” Haematologica (2023). PMID: 37381778 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism, 11. Complications, 12. Prognosis & Natural History - [39]
Rees MJ, Geyer S, Yohannan B et al.. “Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.” Haematologica (2025). PMID: 40400470 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [40]
Sester LS, Milani P, Theodorakakou F et al.. “Characterization, outcome and identification of prognostic factors for patients with systemic immunoglobulin lightchain amyloidosis requiring dialysis prior to initial anticlonal therapy.” Haematologica (2025). PMID: 40534508 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [41]
Vrana JA, Theis JD, Dasari S et al.. “Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.” Haematologica (2014). PMID: 24747948 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [42]
Bryce AH, Ketterling RP, Gertz MA et al.. “Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.” Haematologica (2009). PMID: 19211640 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance - [43]
Granzow M, Hegenbart U, Hinderhofer K et al.. “Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.” Haematologica (2017). PMID: 28341732 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 6. Staging, Risk Stratification & Prognostic Scoring - [44]
Zvida-Bloch T, Muchtar E, Dispenzieri A et al.. “The molecular landscape of AL amyloidosis.” British journal of haematology (2025). PMID: 40211787 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment - [45]
Eby C. “Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.” British journal of haematology (2009). PMID: 19210509 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [46]
Jamroziak K, Zielonka K, Khwaja J et al.. “Update on B-cell maturation antigen-directed therapies in AL amyloidosis.” British journal of haematology (2025). PMID: 39748220 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications - [47]
Wechalekar AD, Hawkins PN, Gillmore JD. “Perspectives in treatment of AL amyloidosis.” British journal of haematology (2007). PMID: 18162121 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [48]
Parrondo RD, Majeed U, Sher T. “Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.” British journal of haematology (2020). PMID: 32298469 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy - [49]
Khwaja J, Vos JMI, Pluimers TE et al.. “Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.” British journal of haematology (2023). PMID: 37726004 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation - [50]
Muchtar E, Gertz MA, Lacy MQ et al.. “Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.” British journal of haematology (2019). PMID: 31298751 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [51]
Tana M, Tana C, Rossi D et al.. “Thromboembolic and bleeding risk in cardiac amyloidosis.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38810701 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management - [52]
Gebbink MF. “Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21781253 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism - [53]
Zanwar S, Rajkumar SV. “Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.” Leukemia (2025). PMID: 40702148 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring - [54]
Sidana S, Larson DP, Greipp PT et al.. “IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.” Leukemia (2019). PMID: 31780812 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [55]
Chen J, Gao XM, Zhao H et al.. “A highly heterogeneous mutational pattern in POEMS syndrome.” Leukemia (2020). PMID: 33262528 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [56]
Nevone A, Girelli M, Mangiacavalli S et al.. “An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.” Leukemia (2022). PMID: 35610346 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 6. Staging, Risk Stratification & Prognostic Scoring - [57]
Mishra AK, Dingli D. “Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.” Leukemia (2019). PMID: 30988378 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [58]
Sidana S, Tandon N, Dispenzieri A et al.. “Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.” Leukemia (2018). PMID: 29483709 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [59]
Dogar S, Punnakanta P, Williams MD et al.. “Tenosynovial and Transverse Carpal Ligament Biopsy for Early Transthyretin Amyloidosis Cardiomyopathy Detection: A Systematic Review and African American Retrospective Cohort Study.” Journal of hand surgery global online (2026). PMID: 42369086 ↗
L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [60]
Fialho ML, Pedreira C, Marback J et al.. “Ophthalmological Manifestations of Hereditary Amyloidosis due to Transthyretin: A Systematic Review.” Journal of ophthalmology (2026). PMID: 42078187 ↗
L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation - [61]
Karaer D, Durak T, Aydin LR et al.. “Next-generation sequencing reveals genetic heterogeneity in MEFV-negative or heterozygous familial Mediterranean fever: a retrospective study.” Expert review of clinical immunology (2026). PMID: 42001281 ↗
L4COHORTCited in: 2. Pathophysiology & Mechanism, 14. Prevention, Screening & Surveillance - [62]
Zhang J, Li Z, Chen H et al.. “Waldenström macroglobulinemia-associated renal AL amyloidosis: a case report and literature review.” Frontiers in immunology (2026). PMID: 42382758 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications - [63]
Xiang S, Bi P, Chen D et al.. “Gelsolin amyloidosis presenting with nephrotic syndrome: a case report and molecular insights.” Frontiers in medicine (2026). PMID: 42232968 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation - [64]
Liao X, Huang X, Yang G et al.. “Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis.” Frontiers in medicine (2026). PMID: 42180761 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [65]
Wang B, Gao R, Cui X et al.. “Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.” Journal of the American Heart Association (2026). PMID: 42132180 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation - [66]
Fontana M, Berk JL, Gillmore JD et al.. “Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.” The New England journal of medicine (2024). PMID: 39213194 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment - [67]
Adams D, Gonzalez-Duarte A, O'Riordan WD et al.. “Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.” The New England journal of medicine (2018). PMID: 29972753 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [68]
Dember LM, Hawkins PN, Hazenberg BP et al.. “Eprodisate for the treatment of renal disease in AA amyloidosis.” The New England journal of medicine (2007). PMID: 17554116 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications - [69]
Wisniowski B, McLeod DSA, Adams R et al.. “The epidemiology of amyloidosis in Queensland, Australia.” British journal of haematology (2019). PMID: 31148162 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy - [70]
Dispenzieri A. “Renal risk and response in amyloidosis.” Blood (2014). PMID: 25301329 ↗
L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [71]
Treon SP. “How I treat Waldenström macroglobulinemia.” Blood (2009). PMID: 19617573 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [72]
Chakraborty R, Zanwar S, Hegenbart U et al.. “Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy.” Blood (2024). PMID: 39197073 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [73]
Quock TP, Yan T, Chang E et al.. “Epidemiology of AL amyloidosis: a real-world study using US claims data.” Blood advances (2018). PMID: 29748430 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management - [74]
Wood WA, Neuberg DS, Thompson JC et al.. “Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.” Blood advances (2020). PMID: 33278301 ↗
L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 11. Complications - [75]
Wechalekar AD, Gillmore JD, Hawkins PN. “Systemic amyloidosis.” Lancet (London, England) (2015). PMID: 26719234 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [76]
Bringhen S, Milan A, Ferri C et al.. “Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).” Haematologica (2018). PMID: 30049825 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 11. Complications, 14. Prevention, Screening & Surveillance - [77]
Pratt G. “The evolving use of serum free light chain assays in haematology.” British journal of haematology (2008). PMID: 18318757 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [78]
Kyle RA, Rajkumar SV. “Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.” British journal of haematology (2007). PMID: 18021088 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [79]
Pinney JH, Smith CJ, Taube JB et al.. “Systemic amyloidosis in England: an epidemiological study.” British journal of haematology (2013). PMID: 23480608 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [80]
Vos JM, Gustine J, Rennke HG et al.. “Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.” British journal of haematology (2016). PMID: 27468978 ↗
L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [81]
Manwani R, Mahmood S, Sachchithanantham S et al.. “Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.” British journal of haematology (2019). PMID: 31388995 ↗
L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [82]
Dispenzieri A, Larson DR, Rajkumar SV et al.. “N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression.” Leukemia (2020). PMID: 32594098 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 14. Prevention, Screening & Surveillance - [83]
Mohamed AN, Chabaklo K, Alzahrani A et al.. “Safety and Efficacy of Left Atrial Appendage Occlusion in Cardiac Amyloidosis: A Single-Center Retrospective Study.” Journal of cardiovascular electrophysiology (2026). PMID: 41528068 ↗
L3COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 13. Special Populations & Pregnancy - [84]
Jung MH, Jung HO, Lee SY et al.. “Temporal Trends and Outcomes of Amyloidosis in Korea: A 14-Year Nationwide Cohort Study.” Journal of clinical medicine (2025). PMID: 41517562 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [85]
Huang S, Luo J, Yu G et al.. “Efficacy and safety of BCMA-directed bispecific antibodies in relapsed and/or refractory systemic AL amyloidosis: A systematic review and meta-analysis.” Leukemia research (2026). PMID: 42309027 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management - [86]
Wang J, Peng K, Li G et al.. “Monoclonal gammopathy of renal significance in western China: A large cohort study dominated by amyloidosis with distinct clinical outcomes.” Clinics (Sao Paulo, Brazil) (2026). PMID: 41671647 ↗
L3COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [87]
Ahmed F, Mirza TR, Iftikhar Z et al.. “Trends and disparities in amyloidosis and cardiovascular disease mortality: a population-based retrospective study in the United States (1999-2020).” BMC cardiovascular disorders (2026). PMID: 41618157 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [88]
Liao J, Pan X. “Systemic light chain cardiac amyloidosis with atrioventricular block.” Frontiers in cardiovascular medicine (2026). PMID: 41584301 ↗
L5CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors - [89]
Kim SY, Kang HS, Lee JE et al.. “Diagnostic challenge of systemic amyloidosis mimicking EGFR-TKI toxicity in lung adenocarcinoma: a case report.” Translational lung cancer research (2025). PMID: 41510372 ↗
L4CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors - [90]
Kumar SK, Hayman SR, Buadi FK et al.. “Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.” Blood (2012). PMID: 22504925 ↗
L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 11. Complications - [91]
Cowan AJ, Skinner M, Seldin DC et al.. “Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.” Haematologica (2012). PMID: 22733017 ↗
L3TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance - [92]
Palladini G, Milani P, Merlini G. “Management of AL amyloidosis in 2020.” Blood (2020). PMID: 33270858 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy - [93]
Merlini G, Stone MJ. “Dangerous small B-cell clones.” Blood (2006). PMID: 16794250 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [94]
Comenzo RL. “LECT2 makes the amyloid list.” Blood (2014). PMID: 24627547 ↗
L5OTHERCited in: 4. Clinical Presentation - [95]
Kyle RA, Benson JT, Larson DR et al.. “Progression in smoldering Waldenstrom macroglobulinemia: long-term results.” Blood (2012). PMID: 22451426 ↗
L3OTHERCited in: 4. Clinical Presentation - [96]
Alameda D, Goicoechea I, Vicari M et al.. “Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.” Blood (2021). PMID: 34133718 ↗
L3OTHERCited in: 4. Clinical Presentation - [97]
Lachmann HJ, Goodman HJ, Gilbertson JA et al.. “Natural history and outcome in systemic AA amyloidosis.” The New England journal of medicine (2007). PMID: 17554117 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History - [98]
Valleix S, Gillmore JD, Bridoux F et al.. “Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.” The New England journal of medicine (2012). PMID: 22693999 ↗
L4OTHERCited in: 4. Clinical Presentation - [99]
Weiss BM, Hebreo J, Cordaro DV et al.. “Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25024082 ↗
L3OTHERCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [100]
Sidana S, Dasari S, Kourelis TV et al.. “IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.” Blood advances (2021). PMID: 33877297 ↗
L3OTHERCited in: 4. Clinical Presentation - [101]
Cook J, Shaikh H, Azzam M et al.. “Clinical Features of Systemic Amyloidosis: A Scoping Review.” Blood advances (2026). PMID: 41603599 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History - [102]
Bønløkke ST, Fenger-Eriksen C, Ommen HB et al.. “Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.” Blood advances (2023). PMID: 37756519 ↗
L2OTHERCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management - [103]
Steinhardt MJ, Muchtar E, Kourelis T et al.. “Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis.” Blood advances (2026). PMID: 41954624 ↗
L3OTHERCited in: 4. Clinical Presentation - [104]
Mahmood S, Palladini G, Sanchorawala V et al.. “Update on treatment of light chain amyloidosis.” Haematologica (2014). PMID: 24497558 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 11. Complications - [105]
Castillo JJ, Garcia-Sanz R, Hatjiharissi E et al.. “Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.” British journal of haematology (2016). PMID: 27378193 ↗
L5OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment - [106]
Chakraborty R, Rosenbaum C, Kaur G et al.. “First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.” British journal of haematology (2023). PMID: 36896578 ↗
L3OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment - [107]
Bodar EJ, Drenth JP, van der Meer JW et al.. “Dysregulation of innate immunity: hereditary periodic fever syndromes.” British journal of haematology (2008). PMID: 19120372 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 13. Special Populations & Pregnancy - [108]
Kastritis E, Wechalekar A, Schönland S et al.. “Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.” British journal of haematology (2020). PMID: 32480420 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 11. Complications - [109]
Kyle RA, Durie BG, Rajkumar SV et al.. “Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.” Leukemia (2010). PMID: 20410922 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [110]
Sidana S, Tandon N, Dispenzieri A et al.. “Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.” Leukemia (2017). PMID: 28919633 ↗
L3OTHERCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management - [111]
Debonnaire P, L'Hoyes W, Dujardin K et al.. “Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study.” European heart journal. Quality of care & clinical outcomes (2026). PMID: 42035239 ↗
L3COHORTCited in: 4. Clinical Presentation, History and Evolution of Treatment - [112]
Zhang B, Yang X, Zhao H. “Idiopathic mesenteric phlebosclerosis initially misdiagnosed as bowel obstruction: a case report.” Frontiers in medicine (2026). PMID: 42145757 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [113]
Sheng LP, Zhang YY, Zhang M et al.. “Case Report: Systemic amyloidosis unmasked by progressive hepatomegaly after splenectomy for non-traumatic spleen rupture in a patient with chronic liver disease.” Frontiers in medicine (2026). PMID: 42100269 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [114]
Garg M, Choudhuri S, Parrish C et al.. “Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.” British journal of haematology (2026). PMID: 42099096 ↗
L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment, 13. Special Populations & Pregnancy - [115]
Pinney J, Roufosse C, Kousios A et al.. “Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper.” British journal of haematology (2025). PMID: 39777620 ↗
L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment - [116]
Kyle RA, Larson DR, Therneau TM et al.. “Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.” The Lancet. Haematology (2014). PMID: 25530988 ↗
L3COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [117]
Aljama MA, Sidiqi MH, Dispenzieri A et al.. “Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.” Blood advances (2019). PMID: 30975646 ↗
L3TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [118]
Bochtler T, Hegenbart U, Heiss C et al.. “Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.” Haematologica (2008). PMID: 18287137 ↗
L3TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [119]
Go RS, Rajkumar SV. “How I manage monoclonal gammopathy of undetermined significance.” Blood (2017). PMID: 29183887 ↗
L5CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [120]
Comenzo RL. “How I treat amyloidosis.” Blood (2009). PMID: 19617578 ↗
L5CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History - [121]
Chakraborty R, Brailovsky Y, Hanna M et al.. “Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps.” Blood (2026). PMID: 41779722 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [122]
Kyle RA, Remstein ED, Therneau TM et al.. “Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.” The New England journal of medicine (2007). PMID: 17582068 ↗
L3OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 12. Prognosis & Natural History - [123]
Mignot A, Bridoux F, Thierry A et al.. “Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.” Haematologica (2008). PMID: 18310532 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [124]
Muchtar E, Dispenzieri A, Wisniowski B et al.. “Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36215675 ↗
L3OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance - [125]
Dimopoulos MA, Gertz MA, Kastritis E et al.. “Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19047284 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 11. Complications - [126]
Pinney JH, Lachmann HJ, Bansi L et al.. “Outcome in renal Al amyloidosis after chemotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21220614 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [127]
Sachchithanantham S, Roussel M, Palladini G et al.. “European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27114592 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment - [128]
Muchtar E, Dispenzieri A, Buadi FK et al.. “From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis.” Blood advances (2025). PMID: 40590881 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [129]
Kukreti V, Seftel MD, Aguirre MA et al.. “American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis.” Blood advances (2026). PMID: 41592868 ↗
L1OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History - [130]
Saunders B, Theodorakakou F, Fotiou D et al.. “Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens.” Blood advances (2025). PMID: 40305663 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [131]
Gustine JN, Staron A, Mendelson L et al.. “Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.” Blood advances (2023). PMID: 37581513 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [132]
Ramirez-Gamero A, Tsakmaklis N, Hunter ZR et al.. “Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia.” Blood advances (2026). PMID: 41118612 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications - [133]
Abdallah N, Dispenzieri A, Muchtar E et al.. “Prognostic restaging after treatment initiation in patients with AL amyloidosis.” Blood advances (2021). PMID: 33595624 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management - [134]
Rauf MU, Law S, Santostefano M et al.. “Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis.” Haematologica (2025). PMID: 40568719 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [135]
Muchtar E, Dispenzieri A, Kumar SK et al.. “Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.” Haematologica (2016). PMID: 27479823 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [136]
Kastritis E, Dimopoulos MA. “Recent advances in the management of AL Amyloidosis.” British journal of haematology (2015). PMID: 26491974 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History - [137]
Rezk T, Lachmann HJ, Fontana M et al.. “Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.” British journal of haematology (2019). PMID: 31124579 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management - [138]
Fotiou D, Theodorakakou F, Spiliopoulou S et al.. “Thrombotic and bleeding complications in patients with AL amyloidosis.” British journal of haematology (2024). PMID: 38321638 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History - [139]
Cohen OC, Wechalekar AD. “Systemic amyloidosis: moving into the spotlight.” Leukemia (2020). PMID: 32269317 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [140]
Gavriatopoulou M, Musto P, Caers J et al.. “European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.” Leukemia (2018). PMID: 30038381 ↗
L1REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [141]
Muchtar E, Gertz MA, Kourelis TV et al.. “Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.” Leukemia (2019). PMID: 31758090 ↗
L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, History and Evolution of Treatment, 12. Prognosis & Natural History - [142]
Zhang S, Wan Z, Hu Y et al.. “AI-assisted diagnosis of cardiac amyloidosis using electrocardiograms and echocardiography: a multicenter retrospective study in China.” BMC medicine (2026). PMID: 42277821 ↗
L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 14. Prevention, Screening & Surveillance - [143]
Kardaş RC, Yıldırım D, Kaya B et al.. “Glomerulonephritis in Takayasu arteritis is dominated by mesangial and AA amyloid lesions and often arises during remission: a case-based review.” Rheumatology international (2026). PMID: 42283880 ↗
L4SR_OBSCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 11. Complications, 14. Prevention, Screening & Surveillance - [144]
Espinoza Romero C, De Barros Correia E, De Siqueira Carvalho A et al.. “High-performance multicenter Echocardiographic diagnostic score for Transthyretin Cardiac amyloidosis: results from the REACT-SP multicenter retrospective Cohort study.” Heart & lung : the journal of critical care (2026). PMID: 42284705 ↗
L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring - [145]
Song B, He Y, Liu X et al.. “Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 42338731 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [146]
Reznik EV, Iarovoi MD, Romanova TS et al.. “Prolonged Infections and Inflammatory Diseases in Common Variable Immune Deficiency as a Cause of AA Amyloidosis.” Journal of clinical medicine (2026). PMID: 42278892 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 11. Complications - [147]
Pattnaik SA, Ahamed H, Gutjahr G et al.. “Extracellular Volume Mapping by Cardiac MRI Predicts Sudden Cardiac Death in AL Amyloidosis: A South Asian Cohort Study.” Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion (2025). PMID: 42333160 ↗
L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling - [148]
Siquara-de-Sousa AC, Hacker M, Vital RT et al.. “Peripheral nerve biopsy in pure neural leprosy: a 26-year experience in Brazil.” Brain communications (2026). PMID: 42428751 ↗
L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management - [149]
Kastritis E, Papassotiriou I, Terpos E et al.. “Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.” Blood (2016). PMID: 27166361 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [150]
Dinner S, Witteles W, Witteles R et al.. “The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.” British journal of haematology (2013). PMID: 23432783 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [151]
Bristogiannis S, Khwaja J, Lwin Y et al.. “Is there a representative quality-of-life questionnaire for patients with AL amyloidosis?-systematic literature review.” British journal of haematology (2023). PMID: 37194132 ↗
L5SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [152]
Kimmich CR, Terzer T, Benner A et al.. “Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.” Blood (2020). PMID: 32107537 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [153]
Lilleness B, Ruberg FL, Mussinelli R et al.. “Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.” Blood (2018). PMID: 30333122 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [154]
Palladini G, Milani P, Foli A et al.. “Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.” Blood (2017). PMID: 29101236 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [155]
Palladini G, Dispenzieri A, Gertz MA et al.. “New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23091105 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [156]
Khwaja J, Kirkwood AA, Milani P et al.. “New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41353737 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [157]
Kastritis E, Wechalekar AD, Dimopoulos MA et al.. “Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20085941 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, History and Evolution of Treatment, 11. Complications - [158]
Aljama MA, Sidiqi MH, Lakshman A et al.. “Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.” Blood advances (2018). PMID: 30463914 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [159]
Berumen A, Staron A, Kalaitzidis G et al.. “Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era.” Blood advances (2026). PMID: 41995749 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [160]
Muchtar E, Palladini G, Schonland S et al.. “Hepatic response criteria in light chain amyloidosis: a multicenter validation study.” Haematologica (2026). PMID: 41537335 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [161]
Dittrich T, Benner A, Kimmich C et al.. “Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.” Haematologica (2019). PMID: 30655373 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [162]
Palladini G, Milani P, Foli A et al.. “Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.” Haematologica (2013). PMID: 24213149 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [163]
Sidiqi MH, Aljama MA, Jevremovic D et al.. “Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.” Haematologica (2018). PMID: 29674497 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [164]
Li T, Huang X, Wang Q et al.. “A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement.” British journal of haematology (2019). PMID: 31348519 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [165]
Meng F, Li J, Zhao R et al.. “Myocardial work indices in the short-term prognosis of light-chain cardiac amyloidosis: Incremental value beyond traditional staging models and echocardiographic parameters.” British journal of haematology (2025). PMID: 40967888 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 12. Prognosis & Natural History - [166]
Giles HV, Wechalekar A, Pratt G. “The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?” British journal of haematology (2022). PMID: 35514140 ↗
L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring - [167]
Muchtar E, Dispenzieri A, Kumar SK et al.. “Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.” Leukemia (2016). PMID: 27904139 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management - [168]
Hwa YL, Gertz MA, Kumar SK et al.. “Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.” Leukemia (2019). PMID: 30737485 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management - [169]
Pons-Fuster E, Riquelme-Perez A, Shumbar V et al.. “Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study.” Cancers (2026). PMID: 42352458 ↗
L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance - [170]
Li X, Xin A, Ai G et al.. “Incremental Prognostic Value of Heart-Type Fatty Acid Binding Protein in Patients With Light Chain Cardiac Amyloidosis: A Prospective Cohort Study.” Clinical and translational science (2026). PMID: 41995132 ↗
L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [171]
Almaadawy O, Mostafa N, Elbataa A et al.. “Impact of cardiac amyloidosis on survival in aortic stenosis patients undergoing TAVR: a systematic review and reconstructed time-to-event meta-analysis.” The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2026). PMID: 42340563 ↗
L1SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance - [172]
Venturiello D, Vignaroli W, Nasso G. “AI-enhanced electrocardiography as a digital biomarker platform in cardiovascular medicine: clinical applications, validation gaps and future implementation pathways.” Open heart (2026). PMID: 42425720 ↗
L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring - [173]
Sessa A, Zaroui A, Charles M et al.. “Hepatic multimodal phenotyping in AL amyloidosis with cardiac involvement: the D-Amy-LIPHE study.” Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2026). PMID: 42406525 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [174]
Bønløkke ST, Ommen HB, Hvas AM. “Altered Fibrinolysis in Hematological Malignances.” Seminars in thrombosis and hemostasis (2021). PMID: 34058766 ↗
L2SR_OBSCited in: 7. Acute & Emergency Management - [175]
Berrocal C, Arbeláez-Cortés Á, Arellano A et al.. “PR3-ANCA-Associated Vasculitis in IgGκ MGUS: A Fatal Case of Rapidly Progressive Glomerulonephritis.” Journal of clinical medicine (2026). PMID: 41976855 ↗
L4CASE_REPORTCited in: 7. Acute & Emergency Management - [176]
Agresti N, Lalezari JP, Amodeo PP et al.. “Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.” Journal of translational autoimmunity (2021). PMID: 33521616 ↗
L4CASE_REPORTCited in: 7. Acute & Emergency Management - [177]
Marchetta M, Adamo L, Bonaventura A et al.. “ABCDE of complex pericarditis cases.” Heart (British Cardiac Society) (2026). PMID: 42045051 ↗
L5OTHERCited in: 7. Acute & Emergency Management - [178]
Lyons G, Thompson J, Lousada I et al.. “Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database.” Open heart (2025). PMID: 40185502 ↗
L3OTHERCited in: 7. Acute & Emergency Management - [179]
Lehmann DH, Gomes B, Vetter N et al.. “Prediction of diagnosis and diastolic filling pressure by AI-enhanced cardiac MRI: a modelling study of hospital data.” The Lancet. Digital health (2024). PMID: 38789141 ↗
L4OTHERCited in: 7. Acute & Emergency Management - [180]
Dhont S, Verbrugge FH, Verwerft J et al.. “Non-invasive imaging in acute decompensated heart failure with preserved ejection fraction.” European heart journal. Acute cardiovascular care (2024). PMID: 38683589 ↗
L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management - [181]
Lebel E, Kastritis E, Palladini G et al.. “Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study.” Cancers (2023). PMID: 36980596 ↗
L4OTHERCited in: 7. Acute & Emergency Management - [182]
Palladini G, Kastritis E, Maurer MS et al.. “Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.” Blood (2020). PMID: 32244252 ↗
L4RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [183]
Gertz MA, Cohen AD, Comenzo RL et al.. “Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.” Blood (2023). PMID: 37366170 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [184]
Maurer MS, Kale P, Fontana M et al.. “Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.” The New England journal of medicine (2023). PMID: 37888916 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [185]
Jaccard A, Moreau P, Leblond V et al.. “High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.” The New England journal of medicine (2007). PMID: 17855669 ↗
L1RCTCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment, 12. Prognosis & Natural History - [186]
Kastritis E, Leleu X, Arnulf B et al.. “Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32730181 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [187]
Wechalekar AD, Dispenzieri A, Sanchorawala V et al.. “Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 42212672 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [188]
Parker TL, Rosenthal A, Sanchorawala V et al.. “Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).” Blood (2025). PMID: 40925099 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 11. Complications - [189]
Coelho T, Adams D, Silva A et al.. “Safety and efficacy of RNAi therapy for transthyretin amyloidosis.” The New England journal of medicine (2013). PMID: 23984729 ↗
L1TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [190]
Fontana M, Solomon SD, Kachadourian J et al.. “CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.” The New England journal of medicine (2024). PMID: 39555828 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [191]
Gillmore JD, Gane E, Täubel J et al.. “Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.” The New England journal of medicine (2025). PMID: 41002250 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [192]
Richards DB, Cookson LM, Berges AC et al.. “Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.” The New England journal of medicine (2015). PMID: 26176329 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [193]
Lebel E, Asherie N, Kfir-Erenfeld S et al.. “Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39653116 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications, 12. Prognosis & Natural History - [194]
Gertz MA, Landau H, Comenzo RL et al.. “First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26858336 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 11. Complications - [195]
Minnema MC, Nasserinejad K, Hazenberg B et al.. “Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.” Haematologica (2019). PMID: 30923094 ↗
L4RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications - [196]
Muchtar E, Gertz MA, LaPlant BR et al.. “Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.” Blood advances (2022). PMID: 35737873 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 11. Complications, 12. Prognosis & Natural History - [197]
Kfir-Erenfeld S, Asherie N, Lebel E et al.. “Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.” Blood advances (2024). PMID: 38768428 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment, 12. Prognosis & Natural History - [198]
Dispenzieri A, Kastritis E, Wechalekar AD et al.. “A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.” Leukemia (2021). PMID: 34168284 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History - [199]
Kastritis E, Anagnostopoulos A, Roussou M et al.. “Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.” Haematologica (2007). PMID: 18024372 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 11. Complications - [200]
Merlini G, Lousada I, Ando Y et al.. “Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.” Leukemia (2016). PMID: 27416985 ↗
L5TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [201]
Landau H, Hassoun H, Rosenzweig MA et al.. “Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.” Leukemia (2012). PMID: 23014566 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [202]
Vianna P, Chakraborty R, Hossain S et al.. “Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.” Blood (2025). PMID: 40712156 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [203]
Wechalekar AD, Sanchorawala V. “Daratumumab in AL amyloidosis.” Blood (2022). PMID: 35507692 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [204]
Chakraborty R, Milani P, Palladini G et al.. “Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies.” The Lancet. Haematology (2023). PMID: 37802087 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [205]
Mahmood S, Bridoux F, Venner CP et al.. “Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.” The Lancet. Haematology (2015). PMID: 26688234 ↗
L4OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History - [206]
Palladini G, Milani P, Foli A et al.. “Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.” Leukemia (2014). PMID: 25059496 ↗
L3CASE_CONTROLCited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History - [207]
Banerjee R, King T, Faiman B et al.. “Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41592262 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [208]
Sidiqi MH, Aljama MA, Buadi FK et al.. “Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29558277 ↗
L4OTHERCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy - [209]
Ford PA, Grant SJ, Mick R et al.. “Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25870085 ↗
L4OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [210]
Ling J, Sidiqi MH, Gertz M. “Management of relapsed/refractory AL amyloidosis.” Blood advances (2026). PMID: 41894688 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy - [211]
Kastritis E, Dialoupi I, Gavriatopoulou M et al.. “Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.” Blood advances (2019). PMID: 31648323 ↗
L4OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications - [212]
Basset M, Milani P, Nuvolone M et al.. “Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.” Blood advances (2020). PMID: 32886751 ↗
L4OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [213]
Palladini G, Merlini G. “Current treatment of AL amyloidosis.” Haematologica (2009). PMID: 19644136 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [214]
Oubari S, Hegenbart U, Schoder R et al.. “Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.” Haematologica (2024). PMID: 37439344 ↗
L2OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [215]
Cani L, Gupta VA, Kaufman JL. “BCL2 inhibition for multiple myeloma and AL amyloidosis.” British journal of haematology (2025). PMID: 40090369 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Complications - [216]
Popkova T, Hajek R, Jelinek T. “Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.” British journal of haematology (2020). PMID: 32072615 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Complications - [217]
Gatt ME, Palladini G. “Light chain amyloidosis 2012: a new era.” British journal of haematology (2013). PMID: 23294331 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Complications, 12. Prognosis & Natural History - [218]
Khwaja J, Ravichandran S, Cohen O et al.. “Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis.” British journal of haematology (2025). PMID: 39980430 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [219]
Landau H, Smith M, Landry C et al.. “Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.” Leukemia (2016). PMID: 27560108 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [220]
Gertz MA. “How to manage primary amyloidosis.” Leukemia (2011). PMID: 21869840 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [221]
Santo C, Correia VM, Defante MLR et al.. “Mortality in octogenarian patients with transthyretin amyloidosis treated with tafamidis: a systematic review and meta-analysis.” Orphanet journal of rare diseases (2026). PMID: 42265773 ↗
L1SR_OBSCited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy - [222]
Niazai A, Zurmati BM, Shah ST et al.. “Vutrisiran in transthyretin amyloid cardiomyopathy: a structured review of the HELIOS-B trial and its secondary analyses.” BMC cardiovascular disorders (2026). PMID: 42271253 ↗
L5SR_OBSCited in: 8. Long-term & Definitive Management, 11. Complications, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance - [223]
Kutsakina DA, Chernichkina AD, Nikolaeva NA et al.. “Crohn's Disease and Axial Spondyloarthritis: From Systemic Inflammation to Amyloidosis.” Journal of clinical medicine (2026). PMID: 42279049 ↗
L4CASE_REPORTCited in: 8. Long-term & Definitive Management, 11. Complications - [224]
Yamaguchi R, Murata Y, Kawamoto S et al.. “Combined Immunoglobulin Heavy- and Light-Chain Amyloidosis Associated With Waldenström Macroglobulinaemia: A Case Report With Diagnostic Challenges and a Favourable Treatment Outcome.” Nephrology (Carlton, Vic.) (2026). PMID: 42265905 ↗
L4CASE_REPORTCited in: 8. Long-term & Definitive Management - [225]
Nizam NB, Beecy AN, Groenendyk JW et al.. “Cardio amyloid-artificial intelligence: advanced multi-modal screening for transthyretin cardiac amyloidosis in severe aortic stenosis patients.” European heart journal. Digital health (2026). PMID: 42427357 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [226]
Muchtar E, Gertz MA, Kumar SK et al.. “Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.” Blood (2017). PMID: 28126928 ↗
L2TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [227]
Schönland SO, Lokhorst H, Buzyn A et al.. “Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.” Blood (2005). PMID: 16293611 ↗
L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [228]
Sidiqi MH, Aljama MA, Muchtar E et al.. “Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.” Blood advances (2018). PMID: 29615413 ↗
L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [229]
Perfetti V, Siena S, Palladini G et al.. “Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.” Haematologica (2006). PMID: 17145600 ↗
L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [230]
Gertz MA, Lacy MQ, Dispenzieri A et al.. “Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.” Haematologica (2007). PMID: 17768110 ↗
L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [231]
Sarosiek S, Lee MH, Doros G et al.. “Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.” Transplantation and cellular therapy (2023). PMID: 37607644 ↗
L4TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [232]
Kfir-Erenfeld S, Asherie N, Grisariu S et al.. “Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36107221 ↗
L4TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [233]
Rodrigues N, Costa C, Branco C et al.. “Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study.” Journal of nephrology (2023). PMID: 38019417 ↗
L2COHORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [234]
Wang Y, Zhang K, Suo X et al.. “B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.” ESC heart failure (2023). PMID: 37909849 ↗
L4CASE_REPORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [235]
Lerman B, Schönland S, Hegenbart U et al.. “Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.” Bone marrow transplantation (2026). PMID: 42332218 ↗
L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [236]
Wu X, Landau H, Liu JE et al.. “Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.” CA: a cancer journal for clinicians (2026). PMID: 42258481 ↗
L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [237]
Blosser CD, Barbir EB, Shaikhouni S et al.. “Malignancy and Kidney Transplant: Core Curriculum 2026.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2026). PMID: 42167833 ↗
L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [238]
Sheng X, Zheng Q, Xiang J et al.. “Romiplostim N01 accelerates platelet engraftment in autologousstem cell transplantation using non-cryopreserved peripheral blood stem cells for plasma cell neoplasms.” Frontiers in immunology (2026). PMID: 42093993 ↗
L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [239]
Huang X, Wu X, Chen W et al.. “B -Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor- T -Cell Therapy for Relapsed or Refractory AL Amyloidosis.” Journal of the American Society of Nephrology : JASN (2026). PMID: 41920709 ↗
L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy - [240]
Basali D, Chakraborty R, Rybicki L et al.. “Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.” British journal of haematology (2020). PMID: 32012228 ↗
L4TRIAL_NONRANDOMCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [241]
Conceição I, Berk JL, Weiler M et al.. “Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.” Journal of neurology (2024). PMID: 39138650 ↗
L2RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [242]
Bever KM, Masha LI, Sun F et al.. “Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.” Haematologica (2015). PMID: 26452981 ↗
L2OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [243]
Gertz MA, Lacy MQ, Lust JA et al.. “Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis.” Haematologica (2008). PMID: 18641023 ↗
L2OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [244]
Bird JM, Fuge R, Sirohi B et al.. “The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.” British journal of haematology (2006). PMID: 16822294 ↗
L4OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy - [245]
Lacy SC, Kinno M, Joyce C et al.. “Direct Oral Anticoagulants in Patients With Cardiac Amyloidosis: A Systematic Review and Meta-Analysis.” International journal of heart failure (2023). PMID: 38303916 ↗
L2SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [246]
Nong Q, Liang S, Zhu W et al.. “Direct Oral Anticoagulants vs. Vitamin K Antagonists for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta-analysis.” Reviews in cardiovascular medicine (2025). PMID: 40160592 ↗
L2SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [247]
Huang W, Frederich A, Nurhafizah A et al.. “Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis.” The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2025). PMID: 40067567 ↗
L2SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [248]
Napolitano A, Toffanin S, Bulato C et al.. “Cryptogenic ischemic stroke in cardiac transthyretin amyloidosis and sinus rhythm: a case report.” Frontiers in cardiovascular medicine (2024). PMID: 38803660 ↗
L4CASE_REPORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [249]
Tersalvi G, James JK, Attia ZI et al.. “Artificial Intelligence Application and Future Directions in Infiltrative and Inflammatory Cardiomyopathies: A State-of-the-Art Review.” Journal of cardiac failure (2026). PMID: 42128582 ↗
L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [250]
Duque ER, Tepetes NL, Kourek C et al.. “Tailoring heart failure management in cardiac amyloidosis.” Heart failure reviews (2026). PMID: 41957254 ↗
L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [251]
Johner N, Notaristefano F, Vlachos K et al.. “Anticoagulation and thromboembolic risk management in pharmacological and electrical cardioversion of atrial fibrillation: State of the evidence and knowledge gaps.” Trends in cardiovascular medicine (2026). PMID: 41933708 ↗
L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [252]
Bukhari S, Sheikh FH, Kelle S et al.. “Clinical and imaging profiling of restrictive cardiomyopathies: insights into amyloid, sarcoid, and iron overload phenotypes.” Heart failure reviews (2026). PMID: 41896355 ↗
L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [253]
Rahmanian M, Khoshandam M, Mousazadeh M et al.. “CRISPR in Medicine: A Systematic Review of Clinical Trials and Therapeutic Applications.” Human gene therapy (2026). PMID: 41810550 ↗
L1TRIAL_NONRANDOMCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [254]
Barosi G, Boccadoro M, Cavo M et al.. “Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).” Haematologica (2004). PMID: 15194540 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [255]
Kyle RA, Greipp PR. “Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.” Blood (1978). PMID: 356916 ↗
L1RCTCited in: History and Evolution of Treatment - [256]
Kyle RA, Gertz MA, Greipp PR et al.. “A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.” The New England journal of medicine (1997). PMID: 9110907 ↗
L1RCTCited in: History and Evolution of Treatment - [257]
Gertz MA, Lacy MQ, Lust JA et al.. “Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (1999). PMID: 10458241 ↗
L1RCTCited in: History and Evolution of Treatment - [258]
Kastritis E, Papassotiriou I, Merlini G et al.. “Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.” Blood (2018). PMID: 29386197 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [259]
Roussel M, Merlini G, Chevret S et al.. “A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.” Blood (2020). PMID: 32108228 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [260]
Dispenzieri A, Lacy MQ, Zeldenrust SR et al.. “The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.” Blood (2006). PMID: 17008538 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment, 11. Complications - [261]
Cibeira MT, Oriol A, Lahuerta JJ et al.. “A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.” British journal of haematology (2015). PMID: 25974382 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [262]
Arendt BK, Ramirez-Alvarado M, Sikkink LA et al.. “Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.” Blood (2008). PMID: 18567838 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [263]
Ambardekar AV, Bhatt A, Hoekstra M et al.. “Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.” Journal of the American College of Cardiology (2026). PMID: 41885675 ↗
L1GUIDELINECited in: History and Evolution of Treatment, 14. Prevention, Screening & Surveillance - [264]
Sayed RH, Wechalekar AD, Gilbertson JA et al.. “Natural history and outcome of light chain deposition disease.” Blood (2015). PMID: 26392598 ↗
L2OTHERCited in: History and Evolution of Treatment - [265]
Kyle RA, Linos A, Beard CM et al.. “Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.” Blood (1992). PMID: 1558973 ↗
L2OTHERCited in: History and Evolution of Treatment - [266]
Basset M, Milani P, Foli A et al.. “Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.” Blood (2022). PMID: 35772003 ↗
L2OTHERCited in: History and Evolution of Treatment - [267]
Gertz MA, Buadi FK, Hayman SR et al.. “Immunoglobulin D amyloidosis: a distinct entity.” Blood (2011). PMID: 22065594 ↗
L4OTHERCited in: History and Evolution of Treatment - [268]
Lachmann HJ, Booth DR, Booth SE et al.. “Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.” The New England journal of medicine (2002). PMID: 12050338 ↗
L4OTHERCited in: History and Evolution of Treatment - [269]
Miliani A, Bergesio F, Salvadori M et al.. “Familial AL-amyloidosis in three Italian siblings.” Haematologica (1996). PMID: 8641636 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [270]
Gertz MA, Kyle RA, Noel P. “Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (1993). PMID: 8487054 ↗
L4OTHERCited in: History and Evolution of Treatment - [271]
Baldini L, Goldaniga M, Guffanti A et al.. “Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005). PMID: 16034042 ↗
L2OTHERCited in: History and Evolution of Treatment - [272]
Cesana C, Klersy C, Barbarano L et al.. “Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2002). PMID: 11896113 ↗
L2OTHERCited in: History and Evolution of Treatment - [273]
Chung A, Kaufman GP, Sidana S et al.. “Organ responses with daratumumab therapy in previously treated AL amyloidosis.” Blood advances (2020). PMID: 32027745 ↗
L4OTHERCited in: History and Evolution of Treatment - [274]
Hawkins PN, Myers MJ, Lavender JP et al.. “Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.” Lancet (London, England) (1988). PMID: 2898580 ↗
L3OTHERCited in: History and Evolution of Treatment - [275]
McAdam KP, Anders RF, Smith SR et al.. “Association of amyloidosis with erythema nodosum leprosum reactions and recurrent neutrophil leucocytosis in leprosy.” Lancet (London, England) (1975). PMID: 51405 ↗
L4OTHERCited in: History and Evolution of Treatment - [276]
Sheikh FH, Dang J, Fontana M et al.. “Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B.” Journal of cardiac failure (2026). PMID: 42128579 ↗
L2RCTCited in: History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy - [277]
Masri A, Cappelli F, Davis MK et al.. “Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.” Circulation. Heart failure (2026). PMID: 42104840 ↗
L5RCTCited in: History and Evolution of Treatment - [278]
Waddington Cruz M, Berk JL, Parman Y et al.. “Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients.” Muscle & nerve (2026). PMID: 41937511 ↗
L2RCTCited in: History and Evolution of Treatment - [279]
Gillmore JD, Adams D, Weiler M et al.. “Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial.” European journal of neurology (2026). PMID: 41913562 ↗
L2RCTCited in: History and Evolution of Treatment - [280]
Jaccard A, Comenzo RL, Hari P et al.. “Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).” Haematologica (2014). PMID: 24859879 ↗
L4OTHERCited in: History and Evolution of Treatment - [281]
Ravichandran S, Cohen OC, Law S et al.. “Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.” British journal of haematology (2021). PMID: 34189728 ↗
L2OTHERCited in: History and Evolution of Treatment - [282]
Staron A, Verma K, Sanchorawala V. “Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis.” British journal of haematology (2022). PMID: 35499208 ↗
L4OTHERCited in: History and Evolution of Treatment - [283]
Gillmore JD, Tennent GA, Hutchinson WL et al.. “Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.” British journal of haematology (2010). PMID: 20064157 ↗
L4OTHERCited in: History and Evolution of Treatment - [284]
Morra E, Cesana C, Klersy C et al.. “Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.” Leukemia (2004). PMID: 15322559 ↗
L2OTHERCited in: History and Evolution of Treatment - [285]
Visram A, Vachon C, Baughn LB et al.. “Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.” Leukemia (2021). PMID: 34764424 ↗
L2OTHERCited in: History and Evolution of Treatment - [286]
Venner CP, Gillmore JD, Sachchithanantham S et al.. “A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.” Leukemia (2014). PMID: 25027514 ↗
L2OTHERCited in: History and Evolution of Treatment - [287]
Ferdinand KC, Selvaraj S, Alexander KM et al.. “Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.” Heart failure reviews (2026). PMID: 42387069 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [288]
Teng Y, Zhou X, Xiao Y et al.. “Mechanistic Insights Into OSM and IL-31 in Primary Localized Cutaneous Amyloidosis: A Narrative Review.” International journal of dermatology (2026). PMID: 42029085 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [289]
Vaishnav J, Bampatsias D, Boursiquot BC et al.. “Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review.” JACC. CardioOncology (2026). PMID: 42017563 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [290]
Sanchorawala V, Shelton AC, Lo S et al.. “Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.” Blood (2016). PMID: 27381904 ↗
L4TRIAL_NONRANDOMCited in: 11. Complications - [291]
Sanchorawala V, Sarosiek S, Schulman A et al.. “Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.” Blood (2020). PMID: 31978210 ↗
L4TRIAL_NONRANDOMCited in: 11. Complications - [292]
Palladini G, Milani P, Foli A et al.. “A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.” Blood (2017). PMID: 28130212 ↗
L4TRIAL_NONRANDOMCited in: 11. Complications - [293]
Lentzsch S, Lagos GG, Comenzo RL et al.. “Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32083996 ↗
L4TRIAL_NONRANDOMCited in: 11. Complications, 12. Prognosis & Natural History - [294]
Hegenbart U, Bochtler T, Benner A et al.. “Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.” Haematologica (2017). PMID: 28522573 ↗
L4TRIAL_NONRANDOMCited in: 11. Complications, 14. Prevention, Screening & Surveillance - [295]
Basset M, Kimmich CR, Schreck N et al.. “Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.” British journal of haematology (2021). PMID: 34341985 ↗
L2OTHERCited in: 11. Complications - [296]
Jordan TL, Maar K, Redhage KR et al.. “Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells.” Leukemia (2019). PMID: 31796914 ↗
L5OTHERCited in: 11. Complications - [297]
Larsen JT, Kumar SK, Dispenzieri A et al.. “Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.” Leukemia (2012). PMID: 23183428 ↗
L2OTHERCited in: 11. Complications - [298]
Novo G, Stabile F, Di Lisi D et al.. “The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis.” Cardio-oncology (London, England) (2026). PMID: 41664246 ↗
L1SR_OBSCited in: 11. Complications - [299]
Ranjit Anderson N, Dorbala S, Mollee P. “Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis.” Blood (2025). PMID: 40663781 ↗
L5REVIEW_NARRATIVECited in: 12. Prognosis & Natural History - [300]
Kastritis E, Palladini G, Minnema MC et al.. “Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.” Blood (2026). PMID: 42118698 ↗
L1OTHERCited in: 12. Prognosis & Natural History - [301]
Quarta CC, Buxbaum JN, Shah AM et al.. “The amyloidogenic V122I transthyretin variant in elderly black Americans.” The New England journal of medicine (2015). PMID: 25551524 ↗
L2OTHERCited in: 12. Prognosis & Natural History, 13. Special Populations & Pregnancy - [302]
Duarte GS, Machado TLGN, Rodrigues FB et al.. “Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis.” European journal of neurology (2026). PMID: 42266139 ↗
L1SR_OBSCited in: 12. Prognosis & Natural History - [303]
Kristinsson SY, Björkholm M, Andersson TM et al.. “Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.” Haematologica (2009). PMID: 19608666 ↗
L2OTHERCited in: 13. Special Populations & Pregnancy - [304]
Aimo A, Castiglione V, Panichella G et al.. “Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.” ESC heart failure (2026). PMID: 42325163 ↗
L2SR_OBSCited in: 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance - [305]
Menentoğlu B, Arık SD, Prencuva Akyürek P et al.. “Comparative analysis of exon 10 and non-exon 10 variants in children with familial mediterranean fever: a retrospective cohort study.” European journal of pediatrics (2026). PMID: 41801261 ↗
L3COHORTCited in: 13. Special Populations & Pregnancy - [306]
Harada S, Nakajima M, Nomura T et al.. “High prevalence of treatable transthyretin cardiac amyloidosis in cardioembolic stroke: the first systematic cohort study.” Journal of neurology (2026). PMID: 41553541 ↗
L3COHORTCited in: 13. Special Populations & Pregnancy - [307]
Balata M, M Attia A, Gbreel MI et al.. “Cardiac magnetic resonance imaging and cardiac scintigraphy in the diagnosis of cardiac amyloidosis: A meta-analysis of 4866 patients.” Journal of molecular and cellular cardiology plus (2025). PMID: 41159134 ↗
L2SR_OBSCited in: 13. Special Populations & Pregnancy - [308]
Diomede L, Rognoni P, Lavatelli F et al.. “A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.” Blood (2014). PMID: 24665135 ↗
L5OTHERCited in: 14. Prevention, Screening & Surveillance - [309]
Comenzo RL, Zhou P, Fleisher M et al.. “Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.” Blood (2006). PMID: 16439680 ↗
L4OTHERCited in: 14. Prevention, Screening & Surveillance